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 ABSTRACT 
 
Neurological disorders such as Alzheimer’s disease and Parkinson’s disease possess complex 
pathologies that are only partially understood.  As more comprehensive and sophisticated studies 
are implemented in an effort to further understand the underlying pathologies of such disorders, 
the generation of larger and more complex quantitative output is becoming increasingly more 
commonplace.  Extracting relevant biological insight from such output can be challenging and 
often requires the application of sophisticated computational tools that are capable of reducing 
complexity so that potentially biologically relevant patterns can emerge.  In this thesis, two 
machine learning classification algorithms, Linear Discriminant Analysis and Random Forests™, 
are applied to a complex proteomics data set derived from a multi-subject study of human 
Cerebral Spinal Fluid (CSF) using a 2d-gel electrophoresis in an effort to identify novel 
Alzheimer’s disease and Parkinson’s disease biomarkers and the results are reported.  
Additionally, a review of recent proteomic studies focused on the discovery of novel 
Alzheimer’s disease biomarkers within CSF is presented.  Described also is a novel visualization 
tool iTRAQPak, which was successfully applied to the analysis of CSF based iTRAQ™ protein 
expression data sets obtained from a cohort of Alzheimer's disease subjects participating in a 
Phase I drug trial.  
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PREFACE 
 
This thesis consists of four chapters addressing Alzheimer’s disease and proteomics based 
research at several levels.  The first three of these chapters are outlined below.  The remaining 
chapter offers concluding remarks pertaining to work presented in the first three chapters and 
also offers possible avenues for future research. 
A review article is presented in Chapter 1, entitled Alzheimer's disease cerebrospinal 
fluid biomarker discovery: A proteomics approach, which was published in the December 2005 
issue of Current Opinion in Molecular Therapeutics.  This review article contains a 
comprehensive overview of relevant and timely research methods, literature, and research results 
pertaining to the characterization and identification of novel CSF proteins that may someday 
allow accurate diagnosis of Alzheimer’s disease in living individuals.  While encompassing 
research articles prior to its publication in 2005, this review continues to be actively cited and 
remains a useful guide to AD biomarker research methods and literature. 
The second chapter entitled: Biomarker discovery and classification of proteomics data 
using two different classification algorithms, describes the analysis of several proteomics data 
sets using two prominent classification algorithms.  Here, two classification algorithms are 
introduced: Linear Discriminant Analysis and Random Forest.  Both algorithms are then applied 
to several proteomics data sets in an effort to identify groups of proteins that allow the 
algorithms to accurately classify the samples contained within the data sets.  In these analyses, 
samples were obtained from healthy individuals, patients with Alzheimer’s disease, or patients 
with Parkinson’s disease.  Proteins identified as being important by the algorithms are then used 
to blindly classify subjects and are assessed for their ability to accurately classify the samples 
contained within the data sets. 
 In the third chapter, the reader is presented with another previously published work 
entitled: iTRAQPak: an R based analysis and visualization package for 8-plex isobaric protein 
expression data.  This work was published in Briefings in Functional Genomics and Proteomics 
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in February, 2008.  iTRAQ (trademarked by Applied Biosystems) is a mass spectrometry-based 
technology which enables the quantitative analysis of protein expression using a multiplex 
approach that allows up to 8 samples (8-plex iTRAQ) to be analyzed in a single experiment.  The 
often large data sets derived from just a single iTRAQ based experiment can be quite complex 
and a challenge to analyze.  Using the R statistical and visualization environment, the iTRAQ 
package, or iTRAQPak, was developed to help facilitate the visualization and analysis of iTRAQ 
based expression data.  The package offers a number of features to facilitate data analysis, 
including sample normalization, scaling, and plotting methods.  Among the more valuable 
features offered by the package is the expression plotting function, which offers a birds-eye view 
of protein expression patterns within the data using a number of novel visualization approaches. 
The utility of this package is demonstrated through its application to the analysis of 8-plex 
iTRAQ protein expression data obtained from cerebrospinal fluid samples from Alzheimer's 
disease subjects involved in a Phase I drug trial
  vii 
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CHAPTER 1∗ 
ALZHEIMER'S DISEASE CEREBROSPINAL FLUID BIOMARKER DISCOVERY: A 
PROTEOMICS APPROACH 
 
1.1 Introduction 
The ability to accurately and definitely diagnose the presence of Alzheimer's disease (AD) in 
living individuals would have a significant impact on the treatment of this disease. A clinical 
diagnosis can be made with a reasonable degree of accuracy by experienced neurologists; 
however, the identification of reliable biomarkers for AD would significantly improve the 
assessment of the disease and may lead to new targets for intervention, in addition to the ability 
to assess disease state and responses to available treatments. Towards this end, there has been 
significant interest in monitoring the changes in cerebrospinal fluid (CSF) protein expression that 
may result from AD pathology. CSF protein expression may be more representative of changes 
occurring in the brain than changes in serum protein expression, and lumbar puncture is a less 
invasive procedure than brain biopsy for obtaining tissue. CSF contains approximately 2000 
proteins and peptides, and the ability to quantify changes in expression of all of these molecules, 
and to then compare these expression patterns across many individuals is not trivial. One of the 
reasons for the difficulty identifying biomarkers through this approach is rooted in the complex 
biochemistry of the disease. However, an equally important limitation relates to the available 
technologies for profiling protein expression (also known as 'proteomics'). There is no single 
technology capable of reliably monitoring all proteins that are expressed by living systems 
because of the diversity of physical and chemical properties of proteins. Furthermore, there is a 
need for improved algorithms for analyzing data obtained from large-scale proteomics 
                                                
∗ Chapter 1 was published in Current Opinion in Molecular Therapeutics (2005) 7(6):557-64. 
∗ Chapter 3 was published in Briefings in Functional Genomics and Proteomics (2008) 7(2):127-35. 
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experiments such as those that are involved in biomarker discovery. Nonetheless, there are 
several commonly used methods and technologies that show tremendous promise. 
In this review, recent published studies that attempt to identify AD biomarkers within the 
CSF proteome are considered. Generally, the technologies that are employed in this literature fall 
into two categories: gel-based separations followed by mass spectrometry (MS) or liquid-based 
separations followed by MS. The various technologies that are being implemented will briefly be 
discussed, and emerging proteomic technologies and approaches being applied to AD CSF 
biomarker studies from recent published literature will be focused on. None of the approaches 
considered here has gained widespread acceptance by the clinical community, nonetheless, these 
methods show promise and highlight both the advantages and limitations of using proteomics for 
biomarker discovery. 
 
1.2 AD Biomarkers 
AD is the most common form of neurodegenerative dementia among the elderly, is estimated to 
affect between 6 and 10% of the population over the age of 65, and is fatal with no widely 
accepted treatment available to slow or reverse its progression [1]. It is estimated that in the US, 
AD treatment costs range from US $50 billion to $100 billion annually, making it the third most-
costly disease after cardiovascular disease and cancer [1]. There is a desire to better understand 
the molecular pathology of AD, as available diagnostic approaches are not optimal to detect the 
onset, presence or progression of this disease, or to assess the effectiveness of new clinical 
treatments [2]. Clinical diagnosis of probable AD is typically derived through patient evaluation 
or cognitive testing. Patient evaluation may involve the use of established criteria set forth in the 
Diagnostic and Statistical Manual of Mental Disorders (DSM) [3], and by the National Institute 
of Neurological and Communicative Diseases and Stroke/Alzheimer's Disease and Related 
Disorders Association (NINCDS-ADRDA) [4].  Sensitivity of these criteria for AD diagnosis 
ranges from 76to 98% and specificity ranges from 61 to 84% [5]. Cognitive tests may include the 
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use of computerized examination tests or paper-based neuropsychological batteries. However, 
inherent biases in these tests, such as patient variation in cognitive skills, socioeconomic 
background, poor test-taking skills and test anxiety may lead to misdiagnosis [5]. The 
complementary use of computerized tomography, magnetic resonance imaging and positron 
emission tomography scanning technology within a clinical setting is still being established, and 
the efficacies of these technologies for AD diagnosis have been reported with varying ranges of 
sensitivity and specificity measures [6]. The primary challenge is that a definitive diagnosis for 
AD requires a postmortem examination; thus an assessment of probable AD is the best that can 
be routinely achieved by clinical diagnosis. 
This issue is particularly important to consider. The output from any biomarker study is a 
function of the individuals that are studied and the control groups that are used. If the AD group 
contains individuals that have no postmortem confirmation, then a special emphasis must be 
placed on validating those observations in a group with a definitive diagnosis. Furthermore, if the 
control group contains only individuals that have no known neurological disorder at the time of 
sampling, then the observed biomarkers may not be effective in a differential diagnosis. In AD 
biomarker studies, an idealized population would involve premortem CSF samples from AD 
patients with postmortem confirmation and a collection of normal and neurological controls to 
aid in the identification of AD-specific biomarkers. Phenotypic overlap can blur the boundaries 
of differential diagnosis and is likely to confound the identification of disease-specific 
biomarkers by proteomic analysis. AD-like neuropathology often exists in combination with that 
of other disorders, such as Lewy bodies and cerebrovascular disease. This mixture of pathologies 
adversely impacts on the accuracy of clinical differential diagnosis, and highlights the 
importance of obtaining autopsy correlation. Ultimately, the proteome may prove to be an 
excellent means of deconvolving mixed phenotypes ante mortem, but only if biomarkers for the 
individual disorders can be identified first. 
Although these approaches offer an exciting opportunity to discover new biomarkers, 
they also highlight an important challenge in the field. The identification of CSF AD biomarkers 
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involves identifying biomarkers in clinically affected individuals (i.e., antemortem CSF) with 
postmortem confirmation of the disease (i.e., definite diagnosis). Clearly, proteomic studies that 
rely on samples with no postmortem confirmation are of limited use, as the sensitivity and 
specificity of any resulting biomarkers cannot be better than the best clinical diagnosis. The 
analysis of postmortem CSF (such as that which may be obtained upon postmortem examination) 
is certainly not representative of antemortem CSF protein expression because of the many 
biochemical changes that occur upon death (e.g., blood-brain barrier function). Thus, the ideal 
study would involve samples collected antemortem from individuals for which postmortem 
confirmation is available. Furthermore, the ability to diagnose a healthy individual from one with 
AD is relatively straightforward, so the more interesting studies involve the differential diagnosis 
of AD from other dementias. Finally, the study should have a large enough number of samples to 
be statistically meaningful. 
The discovery of disease biomarkers that would allow rapid and non-invasive assessment 
of disease state may assist to alleviate deficiencies in current diagnostic methods, possibly allow 
early detection of the disease, provide a means to monitor progression, and may reduce research 
and development costs of new treatments, in addition to the time required to conduct clinical 
trials. Biomarkers are historically termed as 'analytes in biological samples, any measurement 
that predicts a person’s disease state, or response to a drug', but has evolved to include ‘imaging 
modalities or multi-marker genomic/proteomic panels' [7]. Ideally, a validated panel of AD 
biomarkers would allow an unambiguous determination of disease state. Some of the best known 
putative AD biomarkers include CSF and Aβ42; however, these markers can only contribute to a 
clinical diagnosis and are not accepted as a surrogate for definitive diagnosis. As a result, there is 
interest in the discovery of new protein-based biomarkers using CSF. In this review, 
technologies and studies targeting new CSF biomarkers will be considered and the reader will be 
directed to other important literature assessing well known CSF biomarkers [8]. 
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1.3 CSF 
CSF transports cellular products, metabolites, neurotransmitters and proteolytic fragments [9], 
and is secreted from several central nervous system (CNS) structures, including the choroid 
plexus. A highly regulated blood-brain barrier separates CSF from the peripheral circulatory 
system, and the proteins that are found in the CSF are believed to come either from the brain (~ 
20%) or from blood (~ 80%) [10]. The CSF proteome predominately consists of serum albumin, 
transferrin and immunoglobulin(Ig) isoforms and these represent > 70% of the total proteinin 
CSF [11]. Although the proteins found in CSF derive from multiple sources, the brain-derived 
proteins are generally considered to more likely be relevant in AD biomarker studies. It is easy to 
appreciate that biochemical changes in the brain may lead to changes in CSF protein expression; 
however, it is equally important to recognize that CSF biomarkers might also represent important 
changes in protein expression in the plasma. As a result, it is critical to consider the complex 
dynamics of CSF flow and of changes in protein expression. A major challenge associated with 
the diverse sources of CSF proteins is that there is a very large dynamic range of CSF protein 
expression. Indeed, the diversity of protein expression is estimated to be 12 orders of magnitude 
[12]. This challenge is important because the dynamic range of CSF protein concentrations 
exceeds the dynamic range of proteomic detection technologies, making it especially difficult to 
accurately and consistently identify and quantify CSF proteome constituents using currently 
available methods. 
 
1.4 Immunodepletion and Prefractionation in Sample Preparation 
One common approach to address the issue of the wide dynamic range of CSF protein expression 
is to employ immunodepletion methods to remove the predominant proteins, and there are a 
variety of commercially available kits for carrying out this step. The main benefit to 
immunodepleting these abundant CSF proteins is that the analytical techniques used to study 
CSF can emphasize proteins of lower concentration in a separate experiment from the more 
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abundant proteins. Because of this potential benefit, the use of immunodepletion methods is 
widespread among CSF literature [12,13-15]. The Affinity Removal System immunoaffinity 
column (Agilent Technologies) was used by Maccarrone et al. to remove human serum albumin 
(HSA), transferrin, haptoglobin, IgG, IgA and antitrypsin from CSF samples [12,13]. 
Additionally, Maccarrone et al. observed that immunodepleted samples separated on sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and analyzed by MS enabled 
the identification of 240 less-abundant proteins, and immunodepleted samples sub-fractionated 
by anion exchange chromatography yielded the identification of 112 proteins, while non-
depleted and non-fractionated CSF samples identified only 38 proteins [12,13]. Depletion 
methods used by Ogata et al. [15] allowed 50 proteins to be identified, of which all but three 
were detected in the Maccarrone et al. study [12,13], however six proteins were previously 
unannotated on 2-dimensional gels [15]. An important consideration in the use of these methods 
is that there may be a loss of non-targeted proteins through non-specific binding [16]. There may 
also be a loss of information related to the possible utility of certain cleavage products of the 
predominant proteins as biomarkers. 
Prefractionation methods can be used to distribute sample complexity into multiple, less 
complex samples, prior to analytical analysis and this is a more general approach to simplifying 
mixtures of proteins than immunodepletion. In a study by Yuan and Desidario, a prefractionation 
technique was developed in which CSF samples were separated using a reversed-phase solid-
phase extraction (SPE) cartridge, further partitioned and selectively extracted by organic 
solvents, and finally separated by 2-dimensional protein gel electrophoresis (2DE) [17]. This 
procedure resulted in the identification of 42 proteins, many of which were of very low 
abundance, and 46% of which were not identified by the Maccarrone et al. study [12,13]. The 
development of novel and effective strategies for reducing sample complexity and addressing the 
dynamic range issue are technical limitations that need to be overcome before the full benefit of 
proteomics in CSF biomarker discovery can be achieved. 
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1.5 General Proteomic Methods 
There are two basic strategies for CSF protein biomarker studies: gel- and liquid-based 
separations. Both of these approaches are often followed by some type of MS. The use of 
'upstream separations' (either gel or liquid) is required because the mass spectrometers currently 
available are unable to simultaneously analyze more than a few proteins in a single analysis at 
any given time. The resolution of the mixture of approximately 2000 proteins and peptides in 
CSF into simpler fractions that can be studied by the mass spectrometer individually, greatly 
improves the likelihood of identifying meaningful changes in protein expression. A mass 
spectrometer is an instrument that measures the mass of molecules with high accuracy and 
includes two key steps, the ionization of the analyte into charged gas phase ions and the 
determination of the mass to charge ratio of those ions. A mass spectrometer is typically used for 
the final analysis of CSF proteins because it can uniquely identify an unknown protein based on 
a computer analysis of mass spectra compared to an available sequence database. For example, 
an unknown protein that has been resolved by gels or liquid separations can be identified in 
terms of the underlying gene as well as many post-translational modifications that have occurred 
to that unknown protein using a mass spectrometer. Furthermore, in certain experiments, the 
mass spectrometer can be used to quantify the change in expression level of a given protein 
across multiple samples, although most of the biomarker studies to date rely on quantification 
using gel-based separations or other methods as described below. 
 
1.6 Biomarker Studies Using Gel-Based Separations 
In 2DE, the proteins from a given sample are collected and separated first by isoelectric point 
and then by size using the techniques of isoelectric focusing (IEF) and SDS-PAGE. Since charge 
and size are independent characteristics for a given protein, this gel-based technique (originally 
developed in 1975 [18]) has unsurpassed resolution compared with other available methods. 
Anecdotal reports include the ability to resolve complex mixtures of proteins into as many as 
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10,000 features on a gel. After separation by SDS-PAGE, proteins are fixed into the gel and are 
often stained with a total protein stain, an example of which is shown in Figure 1.1. The 
underlying assumption is that the stain intensity of the spots that appear on the gel relates to the 
quantity of the protein present. Thus, by comparing changes in spot intensity across multiple gels 
derived from the CSF proteins from multiple individuals, one might be able to identify changes 
in protein expression that relate to a given disease state. The process by which images are 
compared is facilitated by several commercially available software packages. This general 
approach has some important technical limitations that need to be considered. Firstly, not all 
proteins can be resolved well by 2DE; in particular, small, large, very acidic, very basic and 
many hydrophobic proteins are not resolved clearly on 2DEimages [19]. Secondly, the 2DE 
procedure is extremely laborious, time-consuming and not amenable to automation. For example, 
only a few samples can be run per week by an experienced technician. Furthermore, because of 
the complexity of the protocol, there are many opportunities to introduce errors in the 
experiment, leading to somewhat limited laboratory-to-laboratory reproducibility (undesirable in 
the context of biomarkers). Thirdly, the available software packages for image analysis cannot 
robustly handle certain aspects of the resulting images, including technical artifacts and certain 
posttranslationally modified protein forms. As a result, a very careful image analysis of many gel 
images may take many days or weeks to complete and requires significant labor. Nonetheless, 
this 2DE approach has been commonly used to build CSF protein maps [20,21] and in 
biomarkers studies, because (i) unlike other methods, it is scalable across a large number of 
samples, (ii) it can be used to study changes in the post-translationally modified forms of 
proteins, and (iii) there is an established record of the use of this approach in identifying 
biomarkers for neurodegenerative diseases [20,22-24]. Indeed, the technologies for 2DE have 
evolved to the point where the method is sensitive enough to identify proteins that have never 
previously been reported to occur in CSF [21]. 
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Figure 1.1 A representative 2DE image of CSF from an AD patient 
Proteins are separated by charge in the horizontal direction and by size in the vertical direction. 
Proteins have been visualized with silver stain. A comparison of such 2DE images from a 
number of different individuals can be used to study cerebrospinal fluid (CSF) Alzheimer's 
disease biomarkers. The change in stain intensity can be used as a measure of the amount of 
protein expressed in the CSF of that particular individual. 
 
The outcome of the 2DE analysis of CSF proteins is an image and a series of spots on the 
image that change in stain intensity across samples of interest. By physically isolating those 
spots of interest in the gel and carrying out a sequence-specific protease digestion of the spots, a 
mass spectrometer can then be used to determine the masses of the resulting peptides, in addition 
to amino acid sequence-specific information.  
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As mentioned previously, a key step in the analysis of molecules by a mass spectrometer 
involves the ionization of those molecules prior to mass analysis. The ionization of proteins and 
peptides commonly involves one of two methods: matrix assisted laser desorption/ionization 
(MALDI) or electrospray ionization. Both of these methods work well for the analysis of 
proteins, but neither works well for all types of proteins. Thus, many laboratories have a suite of 
mass spectrometers capable of both ionization types. Several studies report the use of 2DE to 
study CSF for AD biomarker discovery [20,25,26]. In the more recent of these studies, Puchades 
et al. compared the CSF proteome of probable AD (n = 7) and non-AD (n = 7) disease patients 
using 2DE-MS to identify altered levels of nine proteins: apolipoprotein A1, apolipoprotein E, 
apolipoprotein J, β-trace, retinol-binding protein, kininogen, α1-antitrypsin, cell cycle 
progression 8 protein and α-1β glycoprotein [26]. Ogata et al. used 2DE-separated CSF proteins 
to explore strategies to stain for phosphoproteins and glycoproteins [15]; such methods may 
prove useful to post-translational modification (PTM) studies of neuropathology in AD and 
biomarker discovery. The role that PTMs may play in AD remains unclear, however two 2DE-
based studies offer methods that may allow further assessment of their relevance [27,28]. 
 
1.7 Biomarker Studies Using Liquid-Based Separations 
The other approach to the study of the CSF proteome that has been used in the literature involves 
liquid-phase separations rather than gel-based separations. These methods may include a single 
separation step or multiple steps and are followed by MS analysis. 
 
1.7.1 Capillary Electrophoresis-MS 
Using thin-walled columns typically coated with a charged material such as silica, capillary 
electrophoresis (CE) is a separation method that can be easily automated and coupled 'on-line' to 
some mass spectrometers. That is, the column eluent can flow directly into a mass spectrometer 
using electrospray ionization. Although CE alone does not offer the same resolution that is 
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available by 2DE, the separations can be carried out significantly faster [21,29].  Because CE is 
simpler than 2DE and can be automated, the separation schemes are far more reproducible than 
other methods [21,29]. While CE-MS has been used in a variety of biomarker studies [29,30,31], 
there is only one recent example of the application of this method to AD CSF studies. Wittke et 
al. compared CSF from healthy volunteers (n = 4) and probable AD patients (n = 8), which 
resulted in the identification of four differentially expressed polypeptides that were 13.4, 11.78, 
11.98 and 4.82 kDa in size [29]. Their technique was especially useful in resolving polypeptides 
in the low-molecular weight (MW) range (0.8to 15 kDa), in which 450 polypeptides were 
identified. In a comparable 2DE-based study of CSF, approximately 50 protein spots in the 0.8- 
to 15-kDa range were identified, but many more (~ 550 protein spots) were identified in the 15- 
to 150-kDa MW range [21]. While the Wittke et al. study did not use well characterized CSF 
samples and did not further characterize the differentially expressed polypeptides identified, the 
investigators demonstrated the important proof-of-principle application of CE-MS technology to 
the study of CSF [29]. 
 
1.7.2 Shotgun Proteomics 
A primary issue with the CE-MS approach is the limited resolution offered by CE alone. As a 
result, there is significant effort underway to employ 'shotgun proteomics’ methods. These 
shotgun experiments usually involve two liquid-phase separations upstream of MS. The most 
common implementation of shotgun proteomics includes a strong cation exchange separation 
(where many fractions might be collected) followed by a reverse-phase high performance liquid 
chromatography (HPLC) experiment for each cation exchange fraction. The eluent from each of 
the HPLC experiments can either be coupled on-line directly into the electrospray ionization 
source of a mass spectrometer, or can be used off-line by applying the column eluent as 
nanoliter-sized fractions onto a MALDI target plate (this approach is often called liquid 
chromatography (LC)-MALDI). Because these methods rely on multiple dimensions of LC prior 
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to MS, they are often referred to as 2DLC or MDLC experiments. A key feature of this approach 
is that the entire protein content of the sample of interest (e.g., CSF) is initially digested into a 
highly complex mixture of peptides (e.g., 100,000 tryptic peptides) using a sequence-specific 
protease. The resulting mixture of peptides is then separated and studied by MS and the entire set 
of MS spectra are compared against available sequence databases. A key limitation of the 
shotgun approach as applied to biomarker discovery is that these methods are not easily scaled 
for studies involving a large number of samples and there are at least two reasons for this. 
Firstly, a relatively large amount of time is required to analyze a small number of samples with 
this approach because the data sets are large, the algorithms for assigning mass spectra are not 
yet ideal, and the organization of the resulting data can be complex. Secondly, the technique does 
not acquire information on the same set of proteins from experiment to experiment. 
Although there may be overlap in the proteins studied from one experiment to the next 
over a large number of shotgun analyses, the number of proteins studied in all experiments is 
small. Indeed, the problem is compounded when experiments are carried out in different 
laboratories and using different types of mass spectrometers, and a recent study by six companies 
using 10,000 human cells identified total of 1757 proteins, but only 3% of these proteins were 
identified by all of the groups [32]. On the other hand, these shotgun methods offer an ability to 
measure a broad group of proteins, including hydrophobic proteins and proteins present in 
relatively lower abundance - two classes of proteins that are not well studied by 2DE. The early 
efforts at shotgun proteomics are typically used if only as a descriptive method to determine 
what proteins may be present in the sample. However, the technique is somewhat limited 
because the absence of a particular protein from an analysis does not mean that the protein is 
absent from the sample, it only means that it was not identified during that particular experiment. 
As mentioned previously, the number of proteins observed over a large number of experiments 
can be relatively small. To improve the utility of the shotgun approach, there has been an effort 
to use isotopic or isobaric tags to study multiple samples at once and to determine the expression 
ratio among the samples studied for the proteins observed in the experiment. We provide 
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examples of both of these types of analyses below. For a detailed discussion of the various types 
of mass spectrometers and the fundamentals of shotgun proteomics methods, see references 
[33,34].  Wenner et al. analyzed CSF from healthy, aged individuals using shotgun proteomics 
[14]. They used the standard approach of a strong cation exchange separation and reversed-phase 
separation coupled to quadropole ion trap MS to try to identify as many proteins as possible from 
CSF.  The investigators identified 249 CSF proteins from ten individuals using this strategy. The 
results provide a useful measure of the proteins that may be found in CSF and demonstrate the 
applicability of the shotgun method to study CSF proteins. 
The shotgun approach can quantify changes in protein expression by including either 
isotopic or isobaric tags; details of these methods can be found in references [35,36].Two of the 
most commonly used methods include the isotope-coded affinity tag (ICAT) and isobaric tags 
for relative and absolute quantitation (iTRAQ) reagents. Both of these sets of reagents are used 
to differentially label proteins or peptides derived from different samples. After labeling, the 
proteins or peptides from different samples are combined together and analyzed as a single 
sample using 2DLC and MS. Data analysis relies on the differential labels to distinguish the 
origin of the samples and to establish the expression ratio of the proteins observed in the 
experiment. In the case of ICAT, two samples can be studied in a single experiment, whereas 
with the iTRAQ reagents, up to four samples can be compared in a single experiment. The ICAT 
method can label either peptides or intact proteins, whereas the iTRAQ method can only label 
peptides. Two recent examples of the application of ICAT to CSF studies are cited below. The 
iTRAQ technique is relatively new and there are no reports of the application of this method to 
biomarkers studies. Thus, these examples suggest the possible impact of iTRAQ on biomarker 
studies. 
The use of ICAT to quantify differences in CSF protein expression among elderly 
patients was explored by Zhang et al. [37,38]. In one study, age-related changes in CSF were 
investigated using ICAT [37] and, in the other, ICAT was used to quantify differences in CSF 
between probable AD patients (n = 32) and age-matched controls (n = 31) [38].  The latter study 
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resulted in the identification of 390 CSF proteins, where concentration ratios were calculated for 
42% of these, and differential expression ratios of  20% were found in over half of the proteins 
[38]. The investigators compared their findings with two other CSF AD biomarker studies 
[26,39] and reported that α2-microglobulin was the only consistently increased protein in all of 
these studies. It is important to recognize that each of these studies used complementary and 
different types of analyses to achieve this result [26,37,38,39]. An important feature of the Zhang 
study is the use of an alternate technique, Western analysis, to validate these findings [38].  
Although iTRAQ technology [35] has not yet been applied to the study of CSF, it was used to 
study changes in protein expression from Escherichia coli cultures [40]. Using this technique, the 
expression ratios of > 780 proteins could be quantified in a single experiment and included the 
measurement of low abundance proteins [40]. A comparison of the iTRAQ data to 2DE data 
from the same samples suggested that the coefficient of variation in the iTRAQ measurements 
(0.24) was better than that achieved using 2DE (0.31) [41]. For studies that involve the 
quantification of expression ratios using shotgun proteomics, the iTRAQ method should offer 
better throughput and reliability than other methods. However, the applicability of this approach 
for studies involving a substantial number of patient samples is not clear at this time. 
Biomarker studies using other methods Surface-enhanced laser/desorption ionization 
(SELDI)-MS is an alternate approach for the MS-based identification of biomarkers. Unlike the 
gel- and liquid-based separation methods discussed above, the SELDI technology relies on 
surfaces that have chromatographic properties. CSF proteins can be bound to these surfaces 
based on various physicochemical properties. After attachment, the proteins can be interrogated 
using a time-of-flight mass spectrometer. The advantage of this technology is that there is no 
need for upstream separations so that the sample analysis time is extremely fast. However, the 
technology, as it has been implemented to date, has a few limitations. Firstly, the resolution and 
capabilities of the mass spectrometer are not near the level of the analytical instruments used in 
the gel-based or shotgun proteomics methods. The limited resolution means that proteins cannot 
always be easily and unambiguously identified with this approach. Secondly, the mass range that 
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is studied is small - typically less than a few thousand Daltons. Many proteins exist as larger 
molecules in CSF, and proteolytic degradation, whether by in vivo processes or in vitro storage, 
can occur on a short timescale. Thus, there are questions about the ability of this approach to 
study a representative and reproducible sampling of the CSF proteome. However, improvements 
in technology may begin to address these concerns in the near future. There are several reports 
demonstrating the use of SELDI-MS to study disease biomarkers derived from CSF. In 2003, 
Carrette et al. reported a study of CSF from probable AD patients (n = 9) where the strong 
anionic exchange surface was employed to detect five differentially expressed polypeptides 
compared with controls (n = 10) [39]. Four of these peptides were purified and identified as 
cystatin C, two β2-microglobulin isoforms, a4.8-kDa VGF polypeptide and an unnamed 7.7-
kDapolypeptide. More recently, Lewczuk et al. identified three novel amyloid-β peptides using a 
biochemically treated SELDI chip array containing amyloid-specific antibodies [42]. Sanchez et 
al. demonstrated the use of SELDI-MS to identify a 13.4-kDa CSF protein (later characterized to 
be cystatin C) in a small group of patients (n = 8) with Creutzfeldt-Jakob disease using a copper 
affinity array [43]. 
 
1.8 Conclusion 
There is great promise in the application of proteomic approaches to the discovery of CSF 
biomarkers for Alzheimer’s disease and many other neurodegenerative diseases. There are 
several limitations in the current technology that somewhat hinder progress in the field to date. 
These include issues both with gel- and liquid-based separation strategies. As a result, it is 
important for investigators to use complementary techniques to validate any interesting results 
derived from these MS-based analyses rather than rely on the observations derived from a single 
method. A second important consideration is the need for improved computer algorithms related 
to these efforts. Improvements in image analysis algorithms for comparing 2DE data sets could 
significantly shorten the time required for analyzing the raw gel-based data. Improvements in 
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algorithms for matching MS spectra to sequence databases would help ensure that all of the high 
quality MS data obtained is used most effectively and analyzed quickly. Improvements in the 
availability and application of statistical methods for underspecified data sets (more ‘features' 
than 'samples') would help refine the identification of biomarkers (not discussed in this review). 
A third important issue is the limited availability of clinically well characterized samples for 
inclusion in any such studies. 
Ideally, a large repository of antemortem CSF from a variety of individuals with AD and 
other neurological disorders could be provided to the community for use as a common reference 
set that can be studied using all of these techniques. However, there is limited availability of 
antemortem CSF samples with postmortem confirmation of the disease. As a result, many of the 
proteomics studies to date include the analysis of probable AD samples only or include only a 
very small number of definite AD samples, limiting the statistical significance of the results. 
Despite the current limitations in the field, there is tremendous potential and enthusiasm by the 
community in biomarker discovery. There are ongoing improvements in the technology across 
all of the methods described. These improvements and developments include increases in 
throughput, robustness, sensitivity and dynamic range of the technologies. Much of the 
technological development is motivated by the potential clinical impact of newly discovered CSF 
biomarkers and given the very intriguing preliminary data coming from these efforts; there will 
likely be interesting and useful discoveries in the near future. 
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CHAPTER 2  
BIOMARKER DISCOVERY AND CLASSIFCATION OF PROTEOMICS DATA USING 
TWO DIFFERENT CLASSIFICATION ALGORITHMS 
2   
2.1 Introduction 
A primary objective of biomarker research is to identify molecules that enable accurate clinical 
diagnosis of disease.   One approach to identify biomarkers is through the quantification of the 
expression of genes or proteins that may be related to the underlying physiology of disease.  The 
accurate quantification of these molecules is the major focus for genomics and proteomics.  
Enabling technologies from these fields permit detailed snapshots of gene and protein expression 
dynamics to be obtained.  For example, genomic tools such as the microarray allow the rapid and 
accurate measurement of several thousands of gene transcripts in parallel.  Similarly, proteomics 
methods, including 2D gel electrophoresis (2DGE) and mass spectrometry (MS), offer the ability 
to accurately measure protein expression patterns from complex protein mixtures.  In recent 
years, biomarker research has turned to these fields with the goal of identifying and measuring 
the changes of genes and proteins that allow clinical diagnosis to be achieved at level of accuracy 
previously unobtainable. 
Technologies such as microarray and 2DGE methods are often referred to as high 
throughput methods because of the relatively large numbers of measurements they produce.  
They can offer high resolution insight and, correspondingly, can also produce large amounts of 
data.  Microarray technology can generate hundreds to an upward of millions of data points from 
a single hybridization.  A single 2D gel of cerebrospinal fluid, for example, generates over 2,000 
data points, a single measurement for every detectable protein.  Similarly, an MS based shotgun 
proteomics experiment can generate thousands of spectra from a single sample. 
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Biomarker research based on high throughput methods must have the means to sift 
through these large data sets to discover the genes or proteins that may ultimately prove to be of 
high diagnostic value. To accomplish this, data mining and bioinformatics approaches capable of 
identifying possible relationships, and in particular, ones that may be biologically meaningful, 
are often applied.  Here, there are a number of strategies and computational algorithms that can 
be implemented, and the choice of which to implement is not always straight forward. 
Despite the array of algorithms in use, there are at least two common objectives.  The 
first objective is biomarker discovery.  Here, an algorithm is applied to experimental data derived 
from biological specimens (e.g. blood, serum, spinal fluid, etc.) that have been sampled from 
individuals whom have been clinically diagnosed by some gold standard, ideally one that is 
highly accurate.  Typically, the algorithm is applied to multiple population studies where the 
objective is to identify genes, proteins, or some other molecule that can best discriminate these 
populations.  A study might try to discriminate between diseased and healthy populations, or 
possibly even two closely related diseases.  The second objective is prediction.  Here, sample 
data from an individual is fed to an algorithm that is asked to predict its class (i.e. diseased vs. 
healthy).  Prediction methods can be performed in conjunction with biomarker discovery or 
applied diagnostically.  As part of the discovery process, prediction methods can be used to 
determine the accuracy of putative biomarkers.  If class prediction is performed on a panel of 
known subjects, biomarker accuracy can be assessed by comparing the predicted outcomes with 
the known classifications.  And ultimately, biomarkers that have been demonstrated to have high 
predictive value on large populations could be applied with a certain confidence in a clinical 
setting. 
Additionally, there are a number of characteristics of the data set that can influence which 
algorithm is ultimately chosen for use in a high throughput biomarker study.  The size of the data 
set, more specifically, the number of experimental variables (i.e. the number of genes or 
proteins) is one such characteristic, but other important considerations include: 1) the number of 
observations (e.g. number of biological replicates), 2) missing values in the data set, 3) the 
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number of populations being compared, and 4) the relative number of subjects contained within 
each of the represented populations.  Characteristics such as these are important because the 
outcome of an analysis may be misleading or inaccurate if these factors are ignored.  For 
example, in cases where a data set contains fewer observations than variables, statisticians often 
state that n < p.  In a genomic or proteomic data set, n is the number of subjects, and p is the 
number of genes or proteins measured in the analysis.  Dimensionality issues such as this can 
cause many statistical models to estimate parameters improperly and ultimately lead to 
overfitting [1].  Perhaps not surprisingly, p is typically very large in high throughput experiments 
because of the many different molecules being measured in a single experiment.  Unfortunately, 
a study may possess only a small number of subjects, possibly because the disease of interest is 
rare, or simply due to low enrollment in the study.  As a result, the selection of an approach that 
is capable of dealing with highly dimensional data is critical.   
One of the other factors to consider is “missing value” which can often arise in high 
throughput experiments.  For example, in microarray experiments, missing values occur in a data 
set if there is a scratch on the surface of the microarray, or dust masks the signal of several spots.  
In a 2D gel experiment, missing values arise if spots are unintentionally mismatched or clipped 
from the edge of a gel during image processing.  It is thus important to select an algorithm that 
has the ability to deal effectively with missing values.  Another consideration is the number of 
populations being compared which can impact algorithm selection because some algorithms can 
only compare two populations, while others are equipped to handle two or more.  A final 
consideration are unbalanced data sets which arise when the study populations contain unequal 
numbers of observations, these may lead an analysis method to under sample from the smaller 
population, resulting in a loss of information.  The selection of an appropriate strategy thus 
requires an algorithm capable of dealing with unbalanced populations through class weighting or 
over sampling the underrepresented population.  
It is certainly plausible that a single algorithm will not possess all of the desired 
properties to deal with a particular data set.  In such cases, the application of multiple algorithms 
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may be appropriate.  For example, in the analysis of high dimensional data it is possible to first 
apply a dimension reduction method to the data set to reduce the value of p to a more 
manageable size, and then to apply a classification algorithm.  An example of this two step 
approach can be found in a tumor classification study involving microarray gene expression data 
[2].  This study demonstrates the use of Partial Least Squares (PLS) as a dimension reduction 
technique followed by the use of Quadratic Discrimination Analysis (QDA) for classification.  
Another example of a two step dimension reduction approach is demonstrated in a recent 
microarray based cancer classification study where the use of two dimension reduction 
techniques is explored: singular value decomposition (SVD) and partial least squares (PLS), both 
of which are used with a penalized logistic regression (PLR) technique used for classification 
[1]. 
A two step dimension reduction is not always required, however.  An alternate strategy is 
to implement a classification algorithm that is inherently more robust when applied to data with a 
high dimensional variable space.  For example, many machine learning algorithms perform well 
with high dimensional data.  Typically, machine learning algorithms fall into two categories: 
unsupervised and supervised.  Unsupervised classification methods arrange data based on a 
metric of similarity and find the natural organization of data [3]. Examples of such methods are 
hierarchical clustering, self-organizing maps (SOM), and principal component analysis (PCA).  
Each implements a different metric that ultimately determines how data is organized, and 
inherently, unsupervised methods do not allow the number of classes to be pre-specified.  
Supervised classification methods, on the other hand, allow the number of classes to be pre-
specified.  In other words, the algorithms have a priori knowledge of the number of groups that 
exist in a data set, and attempt to classify data accordingly.  Some examples of supervised 
methods are support vector machines (SVM), artificial neural networks (ANN), decision tree 
learning, and random forests (RF), among others. 
While unsupervised methods are useful for the identification of the underlying 
organization of the data, supervised learning methods are often most aligned with the goals of 
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biomarker studies for several reasons.  First, the number of classes (e.g. diseased vs. healthy) is 
typically known in advance.  Second, supervised learning methods have the ability to discover 
new biomarkers, as well as to predict the class of unknown samples. 
In this chapter, two supervised classification methods are implemented.  The first is 
Fisher’s Linear Discrimination Analysis (LDA), and the other is Random Forest (RF).  
Additionally, both methods are implemented using a gene shaving (GS) approach. GS is a 
process by which training models, such as those constructed by LDA and RF, are iteratively fit to 
training data while removing the least significant variables from the analysis (i.e. shaved from 
the training set) after each iteration.  Here the methods were based on LDA and RF because of 
their demonstrated ability to classify data with a large number of variables.  A gene shaving 
approach was chosen because this approach simplifies variable selection by quickly identifying 
the most important variable combinations and it has also been used in other biomarker studies 
with good success.   
 
2.1.1 Fisher’s Linear Discrimination Analysis 
LDA was first proposed by Sir Ronald Fisher in 1936 [4].  This model closely resembles PCA, 
its unsupervised counterpart, but differs in that it assigns a class label to variables and attempts to 
find a linear combination of variables that best separate represented classes.  While LDA is 
considered an excellent dimension reduction method, it still may perform poorly when n << p, 
and may also be sensitive unbalanced data sets [5].   
 
2.1.2 Random Forests 
The RF algorithm was conceived more recently than LDA and made publicly available to 
research communities by Leo Breiman and Adele Cutler.  It has been applied to a variety of 
applications including the differential expression analysis of microarray data.  As described by 
Breiman and Cutler, class prediction is achieved by the RF algorithm through the construction of 
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many classification trees.  Each classification tree comprises a part of a ‘forest’ and is ‘grown’ 
from training data.  As part of RF training, many classification trees are grown.  To predict the 
class of an unknown sample, the sample data is run down each of the trees within the forest 
resulting in a single classification, or “vote”, from each tree.  The overall classification is 
determined by selection of the class that receives the most “votes”.  The algorithm possesses a 
number of characteristics that make it a robust and ideal method for dealing with high throughput 
biomarker data.  First, it performs an efficient and fast analysis of very large data sets and has the 
ability to analyze a very large number of variables.  Unlike LDA, RF performs well even when n 
< p.  Second, RF effectively manages missing data and unbalanced data sets.  And lastly, in 
addition to class prediction, it estimates the importance of variables used in classification [6]. 
Like most supervised classification models, both LDA and RF implement learning 
algorithms that are first trained to recognize classes present in the data set, and then are asked to 
predict the class of unknown samples.  In practice, trained models must also be validated on a 
test-set that contains samples with known classes; the subject classes are not disclosed to the 
classifier and as a result, the model can be evaluated for accuracy.  Importantly, in the context of 
biomarker discovery, validated models mean it is possible to extract the most important variables 
used in classifying sample data. 
In the following analyses, LDA and RF are applied to two paired-class data sets that 
compare Alzheimer’s disease (AD) subjects with healthy subjects (N), and AD subjects to 
Parkinson’s disease (PD) subjects.  From these analyses, several putative biomarkers are 
identified, and the accuracy of these putative biomarkers is assessed. 
 
2.2 Methods 
2.2.1 Protein Quantification and Identification 
Protein expression data used in these analyses were generated from 2D gel electrophoresis 
(2DGE) separations of cerebrospinal fluid (CSF) samples.  Detailed experimental procedures can 
be found in Finehout et al [7].  Briefly, each CSF sample was prepared and then separated using 
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2DGE; resulting gels were then stained to resolve the separated protein spots.  Stained gels were 
scanned using a laser fluorescence imaging scanner, generating a TIFF image for each gel.  
These images were then analyzed using ImageMaster 2D Platinum (GE Healthcare Life 
Sciences) to quantify the protein expression of gel spots.  The determined protein expression 
values were expressed as a percent volume (% vol.) of the total spot volume for each gel as a 
normalization step.  Protein spots of interest were excised from the gels and identified using MS. 
 
2.2.2 Threshold Method 
The nature of the experimental procedures is such that with image analysis and spot detection 
procedures, partially automated, they and are not perfect.  Very low intensity spots are often 
identified during image analysis and may be spots that are poorly represented among all gels 
analyzed in a given experiment.  Such spots are particularly problematic because of background 
noise and may unnecessarily contribute to variability within the data set.  To minimize the 
possibility of background effects due to the presence of very low intensity spots, a threshold was 
applied to remove these spots from data sets included in these analyses.  For n gels and i spots, 
i1…in spots are excluded if T > mean (i1…in), where T is a specified threshold value.  T is 
expressed as a spot % volume, and for all analyses described, T = 0.001. 
 
2.2.3 GSFLD and RFshave Implementation 
The GSFLD algorithm implements a gene shaving approach using LDA.  The algorithm was first 
described by Jiang et al. where it was used to identify possible lung adenocarcinoma biomarkers 
from microarray data [8].  When applied to the data set which first fits all variables to determine 
which are the most important, and using an importance value calculated for each variable, the 
10% least important variables are iteratively removed from the model. While LDA is capable of 
classifying multiple classes, GSFLD (version 2.0) can only be applied to two-class analyses.  
GSFLD requires only a single training-set as input and classification error-rates are determined 
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by a leave-one-out cross-validation strategy.  As the name implies, the model repeatedly samples 
all but one observation from the training-set; the remaining observation is used to test the 
classification accuracy of selected variables.  GSFLD runs as a command-line Microsoft 
Windows executable file and is available upon request by its authors [8].  
The RF algorithm applied in this section (RFshave) is written in the R statistical 
programming language [9] and was developed specifically for this investigation. It implements 
the R package, randomForest (version 4.5-16) written by Andy Liaw and Matthew Wiener, and 
is based on the FORTRAN release of the algorithm (version 5.0) by Breiman and Cutler.  The R 
and FORTRAN versions are essentially identical; however the R version has a limited ability to 
deal with unbalanced data sets. Like GSLDA, RFshave implements an iterative variable shaving 
strategy. But differently, it removes it removes the single least important variable after each 
iteration, rather than the 10% least important variables. 
 
2.2.4 Leave-One-Out Cross-Validation 
To determine the prediction accuracy of variables selected by GSLDA and rfShave, sensitivity 
and specificity values were calculated using a leave-one-out (LOO) strategy.  This strategy was 
implemented in R using LDA (package: MASS) to assess prediction accuracy.  Training and test 
data are supplied to the LDA model iteratively, such that in each cycle (where the number of 
cycles equals n subjects), one subject is removed from the training-set and classified by the 
model.  Each subject is classified only once and otherwise remains in the training-set.  The 
outcomes of the LDA predictions is used to calculate the number of True Positives, True 
Negatives, True Positives, and False Positives, represented by TP, TN, TP, and FP, respectively.  
Sensitivity is calculated as: TP /(TP + FN), and specificity as: TN/(FP + TN). 
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2.3 Results 
Two sets of analyses were performed using 2DGE protein expression data from CSF sampled 
from AD, PD, and N subjects.  In the first set, biomarker discovery was performed by applying 
GSFLD and RFshave to a paired data set containing AD and N subjects.  This data set is referred 
to the AD x N data set and it contained 2DGE protein expression measures from a total of 19 
subjects (10 AD and 9 N).  These analyses were then repeated, but a paired data set containing 
AD and PD subjects was analyzed instead.  This data set, AD x PD, contained expression 
measures from 19 subjects (9 AD and 10 PD).  A threshold was applied to both the AD x N and 
AD x PD data sets (T=0.001).   
 
2.3.1 GSLDA and RFshave: Biomarker Discovery using AD and N subjects 
The threshold applied to the raw AD x N data set excluded 100 variables, resulting in a new data 
set containing expression measures for 1738 variables.  Both GSLDA and RFshave were applied 
to this new data set and both analyses resulted in a number of significant variables to be 
identified (Table 2.1).  The predication accuracy of the variables was assessed by selecting and 
validating two variable sets (p=4 and p=8) from each analysis (i.e. two sets from the GSLDA 
results and two sets from the RFshave results).  The results of this validation are shown in the 
2x2 tables in Figure 2.1.  For all variable sets selected, the classification accuracy of AD and N 
subjects was achieved with a sensitivity and specificity of 100% and 100%, respectively. 
The proteins and corresponding spot IDs represented by the variables in Table 2.1 are 
specified in Table 2.2.  For the GSLDA results, five of the spots had been previously identified 
as transthyretin, vitamin D binding protein, alpha-1 antitrypsin (two spots), and alpha-1 B 
glycoprotein.  Four of the spots were unknown (Variables: V1356, V714, V942, and V312).  For 
the RFshave results, transthyretin, vitamin D binding protein, alpha-1 antitrypsin (two spots), and 
alpha-1 B glycoprotein were also identified along with four unknowns (Variables: V1356, V42, 
V942, and V312).   
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Table 2.1 Significant variables identified by GSFLA and RFshave: AD x N. 
Shown in these tables are the top p most significant variables identified by GSFLD (A) and 
RFshave (B).  As part of the gene-shaving process, p variables were used for classification of the 
AD and N classes after the least significant variables were iteratively removed from the training-
set.  The errors shown in A were calculated internally by GSFLD using a leave-one-out cross-
validation (GSFLD-LOO-CV) and the out-of-bag (OOB) errors shown in B were calculated 
internally by the RF algorithm. Both the GSFLD-LOO-CV and OOB errors are an indicator of 
classification accuracy. 
 
p Error Varaiables
2 2 V719 V1356
3 2 V719 V1356 V700
4 2 V719 V1356 V700 V714
5 2 V719 V1356 V700 V714 V967
6 2 V719 V1356 V700 V714 V967 V998
7 2 V719 V1356 V700 V714 V967 V998 V194
8 2 V719 V1356 V700 V714 V967 V998 V194 V942
9 2 V719 V1356 V700 V714 V967 V998 V194 V942 V312   A. 
p OOB Error % Varaiables
2 0 V719,V1356
3 5.263 V719,V1356,V967
4 0 V719,V1356,V312,V967
5 5.263 V719,V1356,V967,V312,V700
6 5.263 V719,V1356,V700,V967,V312,V194
7 5.263 V719,V1356,V967,V312,V700,V194,V998
8 0 V719,V1356,V967,V312,V700,V194,V998,V42
9 5.263 V719,V1356,V700,V312,V967,V194,V998,V42,V942   B. 
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Figure 2.1 Leave-one-out cross validation results: AD vs. N 
These 2x2 tables report the accuracy of class predictions as evaluated by the leave-one-out cross-
validation.  The validation was performed using sets of discriminators identified as significant by 
the GSFLD (A, B), and RFshave (C, D) analyses.  The variables selected for use in each 
validation correspond to p = 4 and 8 (Table 2.1): A) V719, V1356, V700, and V714,  B) V719, 
V1356, V700, V714, V967, V998, V194, and V942, C) V719, V1356, V967, and V312 and D) 
V719, V1356, V967, V312, V700, V194, V998, and V42.  C) and D).  A total of 19 subjects 
were included in each validation, 10 AD and 9 N.  The values in each white box represent 
predictive rates, clockwise from the upper left: TP, FP, TN, and FN. 
 
 
 
 
 
 
 
Table 2.2 Variable Identities: AD x N. 
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Shown are the 2DGE spot IDs and protein identities corresponding to variables found to be 
significant by GSFLD (A), and RFshave (B). 
 
 
Variable Spot ID Protein Identity
V719 725 Transthyretin
V1356 1378 Unknown
V700 706 Vitamin D Binding Protein
V714 720 Unknown
V967 974 alpha-1 antitrypsin
V998 1005 alpha-1 antitrypsin
V194 196 alpha-1 B glycoprotein
V942 949 Unknown
V312 314 Unknown  A. 
Variable Spot ID Protein Identity
V719 725 Transthyretin
V1356 1378 Unknown
V700 706 Vitamin D Binding Protein
V312 314 Unknown
V967 974 alpha-1-antitrypsin
V194 196 alpha-1-B glycoprotein
V998 1005 alpha-1-antitrypsin
V42 42 Unknown
V942 949 Unknown   B. 
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2.3.2 GSLDA and RFshave: Classification of AD and PD subjects 
The threshold applied to the raw AD x PD data set excluded 174 variables, resulting in a new 
data set containing expression measures for 1765 variables.  Both GSLDA and RFshave were 
applied to this new data set and both analyses resulted in a number of significant variables to be 
identified (Table 2.3).  As with the AD x N analyses, the predication accuracy of these variables 
was assessed by selecting and validating two variable sets (p=4 and p=8) from each analysis.  
For the variable set resulting from the GSLDA analysis, where p=4, the sensitivity and 
specificity were determined to be 88.89% and 100%, respectively.  For the variable set where 
p=8, the classification accuracy of AD and PD subjects was achieved with a sensitivity and 
specificity of 77.78% and 100%, respectively.  For both variable sets selected from the RFshave 
results, the classification accuracy of AD and PD subjects was achieved with a sensitivity and 
specificity of 100% and 100%, respectively.  The 2 x 2 tables for these validations are shown in 
the in Figure 2.2. 
The proteins and corresponding spot IDs represented by the variables shown in Table 2.3 
are specified in Table 2.4.  For the GSLDA results, four of the spots had been previously 
identified as Complement C3, alpha-1 antitrypsin, albumin and transferrin.  Five of the spots 
were unknown (Variables: V94, V1285, V1039, V665, V747).  
For the RFshave results, only 3 spots were previously identified by MS, these were identified as: 
albumin, alpha-1 antitrypsin, and prostaglandin D2 synthase, along with five unknowns 
(Variables: V1039, V94, V1285, V132, and V747).   
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Table 2.3 Significant variables identified by GSFLD and RFshave: AD x PD 
Shown in these tables are the top p most significant variables identified by GSFLD (A) and 
RFshave (B) and corresponding classification error. Error rate is measure of classification 
accuracy and determined by GSFLD-LOO-CV and OOB for GSFLD and RFshave, respectively. 
 
p Error Varaiables
2 3 V94 V244
3 3 V94 V244 V1285
4 2 V94 V244 V1285 V967
5 2 V94 V244 V1285 V967 V285
6 1 V94 V244 V1285 V967 V285 V1039
7 1 V94 V244 V1285 V967 V285 V1039 V665
8 1 V94 V244 V1285 V967 V285 V1039 V665 V747
9 1 V94 V244 V1285 V967 V285 V1039 V665 V747 V54   A. 
p OOB Error % Varaiables
2 10.53 V1039,V285
3 5.263 V285,V1039,V94
4 5.263 V285,V1039,V94,V1285
5 5.263 V285,V1039,V94,V967,V1285
6 5.263 V285,V1039,V94,V967,V876,V1285
7 5.263 V285,V1039,V94,V876,V967,V1036,V1285
8 5.263 V285,V1039,V94,V967,V1036,V876,V1285,V747
9 5.263 V285,V1039,V94,V967,V1285,V876,V1036,V132,V747   B. 
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Figure 2.2 Leave-one-out cross validation results: AD vs. PD 
These 2x2 tables report the accuracy of class predictions as evaluated by the leave-one-out cross-
validation.  The validation was performed using sets of discriminators identified as significant by 
the GSFLD (A, B), and RFshave (C, D) analyses.  The variables selected for use in each 
validation correspond to p = 4 and 8 (Table 2.3): A) V94, V244, V1285, and V967, and B) V94, 
V244, V1285, V967, V285, V1039, V665, and V747, C) V285, V1039, V94, and V967, and D) 
V285, V1039, V94, V967, V1036, V876, V1285, and V747A total of 19 subjects were included 
in validation, 9 AD and 10 PD. 
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Table 2.4 Variable Identities: AD x PD 
Shown are the 2DGE spot IDs and protein identities corresponding to variables found to be 
significant by GSFLD (A), and RFshave (B). 
 
 
Variable Spot ID Protein Identity
V94 94 Unknown
V244 246 Complement C3
V1285 1304 Unknown
V967 974 alpha-1 antitrypsin
V285 287 Albumin
V1039 1046 Unknown
V665 670 Unknown
V747 753 Unknown
V54 54 Transferrin   A. 
Variable Spot ID Protein Identity
V285 287 Albumin
V1039 1046 Unknown
V94 94 Unknown
V967 974 alpha-1-antitrypsin
V1285 1304 Unknown
V876 883 Prostaglandin D2 Synthase
V1036 1043 Albumin
V132 132 Unknown
V747 753 Unknown  B. 
 
The validation results of the four experiments presented in the previous sections are 
summarized in Table 2.5.  A comparison of the variables and corresponding proteins identified 
by both GSFLD and RFshave were also made to assess outcome similarity.  A number of similar 
variables from both the AD x N and AD x PD data sets were identified by both methods.  These 
similarities are summarized in Table 2.6. 
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 Table 2.5 Sensitivity and Specificity outcomes from each analysis. 
Method Comparison p Senstivity Specificity
GSFLD     AD x N 4 100% 100%
GSFLD     AD x N 8 100% 100%
GSFLD     AD x PD 4 89% 100%
GSFLD     AD x PD 8 78% 100%
RFshave     AD x N 4 100% 100%
RFshave     AD x N 8 100% 100%
RFshave     AD x PD 4 100% 100%
RFshave     AD x PD 8 100% 100%  
 
Table 2.6 Variables identified by both GSLDA and RFshave 
Shown are the significant variables (and corresponding Spot IDs and protein identities) identified 
by both GSLDA and RFshave.  Table A represents variables from the AD x N data set; Table B, 
those found from the AD x PD data set.  Variables shown were among the top 9 most significant 
variables identified by each method. 
 
A B
Variable Spot ID Protein Identity Variable Spot ID Protein Identity
V194 196 alpha-1-B glycoprotein V94 94 Unknown
V700 706 Vitamin D Binding Protein V285 287 Albumin
V719 725 Transthyretin V747 753 Unknown
V942 949 Unknown V967 974 alpha-1 antitrypsin
V967 974 alpha-1-antitrypsin V1039 1046 Unknown
V998 1005 alpha-1-antitrypsin V1285 1304 Unknown
V1356 1378 Unknown  
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It was of interest to determine whether any of the proteins identified in these analyses 
have been previously identified as possible AD or PD biomarkers.  These results are summarized 
in Table 2.7. 
 
Table 2.7 Proteins previously identified as putative AD or PD biomarkers 
 
Protein Identity  Comparison Reference 
Albumin AD x PD AD [10] 
alpha-1 antitrypsin AD x N, AD x PD AD [10] 
alpha-1 B glycoprotein AD x N AD [10] 
Complement C3 AD x PD  
Prostaglandin D2 Synthase AD x PD AD [10] 
Transferrin AD x PD AD [10] 
Transthyretin AD x N AD [10] 
Vitamin D Binding Protein AD x N AD, PD [11] 
 
 
2.4 Discussion and Conclusion 
Both methods applied in this study identified several proteins that have been previously 
identified as potential biomarkers (Table 2.7).  Additionally, the predictive value of these 
biomarkers identified by both methods was quite high as evaluated by the LOO cross-validation.  
The proteins identified by the RFshave approach, had a slightly higher predictive value than that 
of the GSLDA method when classifying the subjects in the AD x PD data set (Table 2.5).  While 
this may indicate that the RFshave approach identified a superior set of classification variables, it 
is interesting to note that the variables identified by the RFshave and the GSLDA methods are 
actually quite similar (Table 2.6).  In fact, when considering only the top 9 variables identified 
by both the RFshave and GSLDA methods, 78% and 66% of the variables were identical for the 
AD x N and AD x PD data sets, respectively.  The consistency of the outcomes between these 
two different methods helps support the validity of these results.  
One limitation of the study presented here is that both data sets possess only 19 subjects.  
This limitation arose from an effort to maintain balanced data sets, and in this study, the numbers 
of N and PD subjects were scarce.  Data sets possessing a small number of observations, 
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regardless of the number of variables it possesses, may not fully represent the population it is 
intended to describe, and it is possible that the predictive value of the proteins identified in study 
would be less when applied to larger populations.    
In conclusion, this work has demonstrated the use of two valuable biomarker discovery 
and prediction methods.  Both methods identified several proteins that were able to predict 
disease state with high sensitivity and specificity.  Additionally, this work adds further support to 
the potential importance of several putative biomarkers that may aid in the prediction and clinical 
diagnosis of Alzheimer’s and Parkinson’s disease.  
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CHAPTER 3∗ 
ITRAQPAK: AN R BASED ANALYSIS AND VISUALIZATION PACKAGE FOR 8-PLEX 
ISOBARIC PROTEIN EXPRESSION DATA 
3   
3.1 Introduction 
The rapidly expanding field of proteomics is advancing the ways in which protein expression 
dynamics can be studied.  Contributing to these advances is the proliferation of mass 
spectrometry (MS) based shotgun proteomics methods that have been introduced in recent years.  
Shotgun methods allow the rapid profiling of complex protein mixtures by coupling high 
resolution separation methods, such as HPLC, with the accurate quantitation and identification 
capacity of MS based technologies.  There are a number of methods to quantify protein 
expression from shotgun experiments including those based on isotope-coded affinity tag and 
isobaric tag for relative and absolute quantitation (iTRAQ™) technologies [1].   
One of the more recently introduced methods is iTRAQ (trademarked by Applied 
Biosystems), which permits multiplex quantitation of up to eight complex protein samples in a 
single analysis. The experimental workflow for isobaric tagging based quantitation is similar to 
traditional single sample HPLC-MS based quantitation methods [2], however multiplexing is 
achieved through the use of isobaric labeling reagents that allow multiple samples to be pooled 
and quantitated independently.  The first version of the technology permitted four samples to be 
multiplexed and the newer versions permit eight sample multiplexing [3].  The 4-plex reagents 
consist of four reporter ions (isobaric tags) which are designated as: 114, 115, 116, and 117, and 
the 8-plex reagents consist of these four, plus four additional tags, designated as: 113, 118, 119 
and 121.  Briefly, unlabeled protein samples are trypsin-digested, labeled using isobaric tags, 
then separated by liquid chromatography (perhaps multiple dimensions), and finally, peptides are 
                                                
∗ Chapter 3 was published in Briefings in Functional Genomics and Proteomics (2008) 7(2):127-35. 
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quantified and sequenced by tandem MS (MS/MS).  The isobaric tags covalently bind to the N-
terminus and lysine (Lys) side chain of peptides during labeling and enable multiplexing because 
they each have the same charge and overall mass, but produce different low mass signatures 
upon MS/MS [4, 5].  This unique characteristic allows otherwise identical peptides from 
different samples to be detected as a single peak by MS and produce a single set of sequencing 
ions in MS/MS, while maintaining the quantitation information from the different samples.  
Absolute and relative quantitation is achieved by determining the MS/MS spectra peak areas 
associated with each of the reporter ions and comparing them. 
As shotgun methods continue to be applied to scientific research studies, it is also 
important to develop tools capable of analyzing the data they generate.  In this report, we 
describe the features, and demonstrate the application, of one such a tool which is intended for 
use with 8-plex expression data.  The tool is developed as a package for use in the R statistical 
programming environment, and is called: iTRAQPak.  It performs routine data transformation 
tasks associated with isobaric tag-based shotgun proteomics expression data analysis, and also 
implements more complex analytical, statistical, and visualization functionality that may allow 
important biological relationships to be identified.  We apply this tool to the analysis of 8-plex 
expression data collected in association with a longitudinal study of two Alzheimer’s disease 
(AD) patients undergoing a passive immunization treatment as part of a Phase I drug trial.  The 
results of this analysis are used to demonstrate the utility of several iTRAQPak functions and 
highlight its visualization approach which provides a novel view of 8-plex expression data.   
 
3.2 Implementation and Overview 
The iTRAQPak package was developed in the R programming language [6]. R is a rich 
statistical, data analysis, and visualization environment that is widely used and freely available 
under the GNU General Public License.  iTRAQPak has been developed and tested under the 
Windows computing environment (Microsoft Windows Server 2003), however R is available 
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under a variety of operating system environments.  Package functions are run from the R 
command line.   
Expression data are imported into R using the iTRAQPak function LoadData.  The 
function expects data to contain a number of required variables; these are shown in Table 3.1.   
Expression data with corresponding variable columns can be generated through the use of 
software such as GPS Explorer (Applied Biosystems) with Mascot (Matrix Science) integration.  
While the set of required variables is fixed, the columnar order of the input variables is 
customizable through command line parameter options which are accessible during data import.   
The package provides a number of data transformation options which can be selectively 
applied to imported data sets using user supplied parameter options.  Transformation options 
include: isotope impurity correction, sample normalization, peak scaling, and log transformation.  
Some form of impurity correction is recommended by the manufacturer for iTRAQ data analysis 
because the labeling reagents contain trace levels of isotopic impurities that cause variations in 
the MS peak intensities.  Applying the impurity correction transformation to a data set adjusts 
peak intensities as specified in the ‘Certificate of Analysis’ by the reagent manufacturer. Table 
3.2 defines the default peak area correction factor applied to each peak type; however these 
values are customizable by modifying parameter input supplied to the package. Various 
normalization procedures can be applied to sample data, and these are intended to correct 
between sample variation that may arise due to  
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 Table 3.1 Required columns and corresponding R data types 
 
Column Description R Data Type 
1 Plate Number numeric 
2 Spot Label character 
3 Protein Name character 
4 Accession Number character 
5 Modification character 
6 Ion Score C.I. % numeric 
7 Best Peptide Sequence character 
8 Start Sequence Position numeric 
9 End Sequence Position numeric 
10 Ion Score numeric 
11 Calculated Mass numeric 
12 Observed Mass numeric 
13 Match Error PPM numeric 
14 Area 113 numeric 
15 Area 114 numeric 
16 Area 115 numeric 
17 Area 116 numeric 
18 Area 117 numeric 
19 Area 118 numeric 
20 Area 119 numeric 
21 Area 121 numeric 
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Table 3.2 Default correction factors 
 
TAG -2 -1 +1 +2 
113 0 2.5 3 0.1 
114 0 1 5.9 0.1 
115 0 2 5.6 0.1 
116 0 3 4.5 0.1 
117 0.1 4 3.5 0.1 
118 0.1 2 3 0.1 
119 0.1 2 4 0.1 
121 0.1 2 3 0.1 
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experimental procedure, rather than from biological differences.  Normalization methods that can 
be applied are based on: 1) sample mean, 2) sample median, and 3) Lowes regression [7].  
Applying peak scaling expresses peak areas as a relative quantitation rather than absolute, and 
parameter settings allow up to two of the tags to be specified as a baseline for relative 
comparison.  For example, with the default peak scaling parameters, areas associated with tags 
115, 117, and 119 are expressed relative to tag 113 associated areas, and the remaining areas are 
expressed relative to 114 associated areas. Finally, scaled data can be Log2 transformed in 
preparation for statistical analysis or to represent expression increases and decreases as positive 
and negative values to allow for a more intuitive visual interpretation when viewed graphically. 
When several peptides with identical sequences are identified during quantitative shotgun 
data analysis, one strategy is to expresses their peak areas as a single averaged area.  The 
advantage of averaging peak areas is that expression values are derived from more than one 
observation and, additionally, data set complexity is also reduced, thus allowing for a more 
simplified interpretation.  However, condensing data using such an approach over-simplifies the 
complexity related to posttranscriptional and posttranslational gene expression [3]; and as a 
consequence, important biological information can be lost.  While peptides may be 
indistinguishable at the amino acid (AA) sequence level, they may be distinguished when 
posttranslational modifications (PTMs) or other modifications are considered.  Ignoring this 
difference may result in important biological relationships being overlooked.   Further, two 
peptides, identical at the sequence level, may actually be from two highly homologous genes that 
have different biological roles.  Averaging, in this case, makes little sense from a biological 
perspective. 
With this in mind, iTRAQPak implements a multitiered strategy to avoid such loss of 
information by representing data at an uncondensed level plus three condensed levels: 1) the 
peptide level, 2) the peptide-modifications level, and 3) the protein level.  Data are condensed by 
averaging grouped peak areas defined by these levels.  At the peptide level, peak areas are 
distinguished by amino acid sequence, and similarly, at the peptide-modifications level, peptides 
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are distinguished by sequence and modification. At the protein level, peak areas are 
distinguished by accession number (GI).  Finally, at the uncondensed level, as the name implies, 
no averaging is performed. 
Peptide expression maps are generated using the iTRAQPak PlotExpression function.  
The expression maps present several different views of expression data, where the data are 
condensed to different levels within several of the views.  Uncondensed expression data are 
displayed using two different view styles.  The first displays expression data using heat maps and 
the second, using expression plots.  Heat-maps are widely used to represent expression change, 
for example, red/green heat-maps are commonly used to represent microarray gene expression 
data, where red typically represents an increase in expression and green, a decrease [8].  A 
similar red/green strategy is used to visually represent relative log-fold changes in peptide 
expression within iTRAQPak peptide expression maps.  Expression plots are displayed as an 
alternative to the heat-map representation, but rather than using color to represent expression 
change, two dimensional line plots are used, where the y-axis represents relative log-fold 
changes in peptide expression.  For both formats, the uncondensed view displays expression 
values of every peptide detected.   Expression plots are also used to represent condensed views 
for both peptide and protein level expression data and are a standard display within expression 
maps.  Because there are a number of modifications that may be of interest in a research study, 
condensed peptide-modifications level data can be optionally displayed within the heat-map 
view, using user supplied parameters. 
Expression map functions also allow peptide-modifications level expression data to be 
presented in an uncondensed form.  Here, the uncondensed peptides displayed in the heat-map 
view are simply highlighted.  Specifying modifications of interest is achieved by supplying 
plotting functions with a parameter list of modification-codes.  Parameter functions also allow 
peptides that lack a particular modification to be highlighted.  As an example, it is possible to 
highlight peptides that possess a Lys residue but lack a [K]-iTRAQ tag.  In the current 
implementation (1.0.7), it is possible to highlight peptides with these modifications: Oxidation, 
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MMTS, [K]-iTRAQ, and [N-Term]-iTRAQ.  Additionally, because the plotting functions search 
the Modifications column of the input data set, modifications that can be specified are limited to 
those present in this column. 
The use of heat-maps in the peptide expression maps is a method implemented to reduce 
the visual complexity of the underlying expression data.  Another method that is implemented is 
self organizing map (SOM) clustering, which is widely used as a data visualization method for 
mapping high-dimensional non-linear data into a lower dimensional visualization space.  Applied 
to expression plots, it allows complex expression patterns to be color coded based on similarity.  
The package implements SOM clustering to color code peptide expression patterns using the 
SOM package available in R. 
Several data quality functions are implemented in the iTRAQPak package, two of which 
are: TagSummary and LabelingEfficiency.  When applied to the raw expression data, 
TagSummary applies several transformation steps to the expression data, groups it by isobaric 
tag, and plots the transformed data to PDF.  The PDF output consists of five plots, the first shows 
Log2 raw data (i.e. the data are not normalized, scaled, nor corrected, but are Log2 transformed) 
peptide expression values grouped by isobaric tag, and the second shows the effects of scaling, 
and the remaining three show the effects of mean, median and Lowes regression normalization.  
The LabelingEfficiency function uses peptide sequence and modification information to evaluate 
the efficiency of labeling reactions and then plots the results.  It is assumed that under ideal 
conditions, the labeling reactions will go to completion such that all N-terminal and Lys residues 
are labeled with an iTRAQ tag.  While this may not be the case under normal experimental 
conditions, it is possible to quantify the abundance of partially and fully labeled peptides.  A 
partially labeled peptide is defined as one that has been labeled with at least one isobaric tag, but 
contains other possible labeling sites that have not been labeled.  As an example, a peptide may 
contain a Lys residue in addition to its N-terminal residue; if it were partially labeled, then only 
the Lys group would be labeled.  Using peptide sequence information, it is possible to assess 
which peptides contain Lys, in addition to N-terminal, residues, and using high confidence 
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search results, it is possible to assess which peptide residues have been labeled by an isobaric 
tag.  Using this information, a relative calculation can be made by summing the areas of all 
partially labeled peptides and expressing this value as fraction of the summed area of fully 
labeled peptides. 
 
3.3 Methods 
To assess the utility of the iTRAQPak package, cerebrospinal fluid samples from two probable 
AD subjects were analyzed using 8-plex technology and methods as described previously [3].  
Both of these subjects were enrolled in a Phase I drug trial investigating the effects of 
intravenous immunoglobulin as an AD treatment.  As part of a longitudinal study, both patients 
received ongoing treatment with IVIg and cerebrospinal fluid (CSF) samples were collected 
(with appropriate consent) by lumbar puncture from each patient over the course of the study. 
In this study, four CSF samples from each AD patient were collected for protein 
expression analysis.  These samples were collected at four different time points: at a baseline 
timepoint at the beginning of the drug treatment regimen, after three months and six months of 
treatment, and then after a subsequent three month drug washout period (i.e. after 0, 3, 6, and 9 
months). CSF was collected and analyzed as described previously [3]. 
 In the R programming environment, the iTRAQPak package was imported and several 
package functions applied to the isobaric tag-based protein and peptide expression data.  As the 
first step of the analysis, the expression data set was imported into R using iTRAQPak’s 
LoadData function. Next, using the TransformData function, peptide expression data were 
corrected for isotopic impurities, median normalized, and scaled.  Using scaling parameter 
options, peptide expression values were scaled relative to the “0” time point (T1) for both 
patients.  Also using the TransformData function, scaled values were then expressed as Log2 
values and subsequently used for statistical and visualization analyses.  Statistical analyses 
applied in this study consisted of three-way analysis of variance (ANOVA) and was performed 
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in R using the lm and anova functions.  Peptide expression maps were generated using the 
PlotExpression function.  To highlight peptides containing modifications of interest, the pepMod 
function was applied to expression data and expression maps were regenerated.  Labeling 
Efficiency plots were created using the LabelingEfficiency function.   Details on how to invoke 
package functions and parameter details are supplied within the iTRAQPak help files. 
3.4 Results and Discussion 
The 8-plex iTRAQ data set contained expression values for 1187 peptides (GPS ion score 
confidence interval 95% or greater) derived from 167 proteins (false positive rate of 0.8%). A 
complete list of proteins and peptides is provided in [3]. Here, we report on the development of 
the iTRAQPak software package and its application to this data set. 
Expression data were imported into R, and several transformation steps were applied to 
the imported data as described in the methods section.  Mean peptide expression levels for each 
of the labeled samples were inspected before and after normalization (Figure 3.1).   Before 
normalization, the mean expression values for peptides labeled with the 113 tag were noticeably 
lower than the mean expression values for the peptides labeled by the other 7 tags.  After 
normalization, this difference was less noticeable.  However, when inspecting the scaled values, 
it was observed that the expression values for samples scaled to the 113 tag labeled sample were 
more variable than the expression values scaled to the 114 tag labeled sample.  This was also 
observed for mean and Lowes regression normalization methods (data not shown).  While 
normalization corrected for some of the between sample variability, it did not correct for all, 
suggesting a more complex level of variability exists for this data. 
Using iTRAQPak functions, peptide expression maps were created for each unique protein 
identified in the normalized and transformed data set.  As an example, the map for albumin is 
shown in Figure 3.2.  Maps were output from R as high-resolution PDF files which allowed them 
to be easily viewed using Acrobat Reader (Adobe Systems).  Acrobat Reader’s search functions 
were useful to quickly search for GI numbers of interest, and additionally, the zoom and scroll 
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features allowed the features of the plots to be more closely inspected.  Detailed views of heat-
map and expression plots for albumin are shown in Figures 3.3 and 3.4, respectively.   
 
 
Figure 3.1 Normalization, Correction, and Scaling of data 
All data presented are in Log base 2.  Panel A shows raw peak area data from each isobaric tag 
prior to correction and normalization. Panel B shows ratio data scaled by the 113 and 114 peak 
areas (for patient A and B respectively). Panel C shows ratio data after isotopic correction and 
median-based normalization. 
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Figure 3.2 Peptide expression map generated by iTRAQPak for the albumin precursor 
protein (gi|4502027) 
The map contains multiple views that present peptide expression values as either an expression 
plot (A-E) or heat-map (F).  Expression values associated with each peptide are presented 
spatially within the context of the albumin precursor protein, where the x-axis indicates each 
peptide’s location within the protein using amino acid numbers as coordinates.  Expression 
values are condensed to either the peptide level (A) or protein level (B, C), or is uncondensed (D, 
E, and F).  Expression data for both patients is also presented.  Pane A contains expression plots 
for both patients and uses colored plot lines to discriminate between the two subjects, with black 
and red representing patients A and B respectively.  Panes B and D represent subject A, and 
panes C and E represent subject B.  The heat-maps in pane F present expression patterns for both 
subjects; Figure 3.3 describes this pane in more detail.   
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The heat-map was found to be an effective method for viewing longitudinal expression 
changes.  For larger proteins (> 1200 AA) or very small peptides (<10 AA), it was found that 
plotting space was noticeably limited, causing peptide blocks to be somewhat compacted. It was 
possible to compensate for this by plotting the PDF output with wider page dimensions (> 13 
inches) or by significantly increasing zoom factor. Both the peptide heat-maps and paired 
expression plots allowed expression profiles to be easily compared.  Additionally, the SOM 
coloring allowed otherwise complex expression patterns to be more easily interpreted. 
The importance of incorporating multilevel views into peptide expression plots was made 
evident after inspecting the heat-map and expression plots.  Figure 3.3 shows several albumin 
peptides with several opposing expression patterns, especially for patient A.  The N-terminal 
peptides (in the10-50 AA region), for example, shows an increase in expression over time (T1 to 
T2), while others show a strong decrease between T1 and T2.  When averaged at the peptide 
level, these opposing expression trends are lost, favoring the decreased expression pattern. 
Figure 3.4 shows a more detailed view of the observed albumin peptides with data shown as 
expression plots for individual peptides. The expression change is plotted log base 2 such that 
increases in expression have positive slope and decreases in expression have a negative slope.  
The pepMod function was applied to the expression data using parameters to highlight 
peptides lacking an N-terminus tag in a newly generated expression map.   Shown in Figure 3.5 
is a zoomed and cropped image of the albumin protein that was generated.  Visual inspection of 
the output showed a number of highlighted peptides allowing us to determine which of the 
peptides shown in the heat-map were lacking an N-terminus tag.  Interestingly, it was observed 
that many of the peptides lacking an  
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Figure 3.3 The iTRAQ analysis identified a number of peptides matching the albumin 
precursor protein amino acid sequence (gi|4502027) 
In this zoom-in of the heat-map view (Pane F, Figure 3.2), the expression patterns for peptides 
corresponding to the first 120 amino acids of this protein are shown.  Each rectangle represents a 
single peptide and contains 8 color graded boxes that indicate expression change; the top four 
boxes correspond to patient A, and the bottom four correspond to patient B.  Columns represent 
the four time points, where expression changes are expressed as a scaled value relative to time 0.  
The magnitude of the change is determined by the color scale.  Peptide rectangles are stacked in 
the direction of the y-axis (Peptide Stack) simply as a means of organizing data presentation. 
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Figure 3.4 Expression plots for several peptides corresponding to the albumin precursor 
protein (gi|4502027) 
Each plot line corresponds to the expression values of a single peptide and represents the 
expression change over time. The x-axis represents the relative location of the peptides within 
the context of the albumin precursor protein, shown here are only peptides that match the 70-100 
amino acid region of the protein. A SOM coloring scheme is applied to each plot line to facilitate 
rapid visualization of similar expression trends; shown here in grayscale, similar shades indicate 
similar expression patterns. 
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Figure 3.5 Modifications highlighting 
Using the pepMod function, peptides containing modifications of interest may be highlighted.  
Peptides lacking an N terminal tag are highlighted in blue, shown here in grayscale, but further 
highlighted with an arrow. 
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Figure 3.6 Quality control measures applied to shotgun data to assess labeling efficiency 
Unlabeled sites, grouped by tag, are quantified as a function of the relative peak areas of partially 
and fully labeled peptides.  Total area is a measure of total protein identified by isobaric tagging 
analysis and is quantified as a function of total peak area, grouped by tag. 
 
 
N-terminus tag also showed a strong decrease in expression over time (0-9 months) for patient A, 
but this was not observed for patient B.  To determine if this relationship was statistically 
significant, a three way ANOVA was applied to the expression data for the peptides highlighted 
in Figure 3.5.  A highly significant interaction was found between the patient and time terms (p < 
0.0001), and a highly significant three-way interaction (p < 0.0001) between the patient, time, 
and modification terms.  These results show that the expression pattern differences between 
Subject A and Subject B are significantly correlated with the lack of an N-terminus tag.  This 
strongly suggests that the different expression patterns seen between Subject A and Subject B are 
due to a labeling effect, rather than a biological effect. 
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To investigate this further, the LabelingEfficiency function was applied to the expression 
data set to determine which if any of the tags may be contributing the observed trends in Figure 
3.5.  The resulting plot from the application of this function is shown in Figure 3.6.  The plot 
shows a noticeable difference in the relative area of unlabeled/labeled peptides associated with 
the 113 labeled sample as compared to the samples labeled by the other seven tags.  From this, 
we can determine that there are relatively more partially labeled peptides in the 113 labeled 
sample as compared to the other seven samples, suggesting the 113 labeled sample was not as 
efficiently labeled as the other seven samples.  Experimentally, all steps were performed 
similarly among the different samples and labels. However, this observation adds support to the 
possibility that the expression patterns observed in Figure 3.5 may be due in part to a labeling 
effect rather than a biological effect.  Further, the observed drop in expression between 0 and 3 
months, for patient A, in peptides lacking an N-terminus tag also supports the observation that 
unlabeled peptides are more abundantly represented in the 113 labeled sample. 
 
3.5 Conclusion 
We developed the iTRAQPak software package to aid in the visualization and interpretation of 
8-plex shotgun proteomics expression data generated from a four time-point longitudinal study 
involving two patients. The isotope impurity and transformation functions available in this 
package facilitate rapid analysis of complex expression data.  The iTRAQPak expression maps 
enable expression data to be viewed on multiple levels using methods that reduce visual 
complexity.  We used the peptide expression maps to reveal complex patterns of expression 
between peptides identified as being fragments of same protein and even peptides with identical 
sequences.  This observed complexity of expression further emphasizes the importance of 
interpreting condensed expression data with caution.  Using the iTRAQPak modifications 
highlighting feature we observed a visual correlation among expression patterns from peptides 
lacking an N-terminal tag and also found this correlation to be statistically significant and 
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possibly related to the labeling efficiency of 113 isobaric tags in these experiments.  While we 
have used this package’s functionality to identify likely factors contributing to experimental 
variation within our data set, the approaches demonstrated here are equally applicable to the 
identification of expression trends that are of important biological significance. Finally, although 
iTRAQPak was developed for 8-plex data sets, it may be applied to 4-plex data sets as well. Data 
from electrospray based analyses could be incorporated if formatted appropriately.  iTRAQPak is 
freely available for non-commercial purposes and can be downloaded from the Comprehensive R 
Archive Network (CRAN): http://cran.r-project.org/.  This is most easily achieved from the R 
interface, first by selecting 'Install Packages' from the 'Packages' menu bar, and then selecting 
iTRAQPak from the packages list. 
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CHAPTER 4 
CONCLUDING REMARKS AND FUTURE DIRECTIONS 
4   
The pathology of AD is quite complex and we are only now beginning to untangle the 
nuances of this disease. AD has been inextricably linked with the buildup of β-amyloid plaques 
within brain tissue; however the ultimate cause of this buildup remains unclear.  A variety of 
models have been proposed to explain this phenomena, proposing the role of a number of 
neurological mechanisms and responses, including blood brain barrier clearance and regulation 
mechanisms, the inflammation response, and the cell death response.  However, none of these 
models fully explain the pathology and many questions remain. 
To fully understand this complex disease, we must first identify key molecular 
constituents, be it genes, proteins, or inorganic molecules that are integral to its pathology.  With 
the knowledge of these compounds in hand, we can begin to piece together their physiology and 
their underlying role in the pathology of the disease.  In Chapter 1, the role of proteomics and the 
study of CSF was discussed and linked to this process of discovery.  Tools such as 2DGE, MS, 
and high throughput methods such as iTRAQ are being used to study important aspects of CSF 
physiology that may further our insight into AD pathology.  While these methods are not without 
their limitations, they offer an unprecedented level of detail, precision, and throughput for 
understanding molecular constituents.  With these tools, we may be able to identify proteins 
integral to the complex pathology underlying AD.  And with the high throughput nature of 
methods such as iTRAQ, it will be possible to sample larger populations of individuals in less 
time than previously possible.  This higher throughput, in the presence of an adequate supply of 
biological samples, may allow us to gain a more complete picture of the AD pathology at the 
individual level and how it may vary within a larger population of individuals. 
In the interim, while we come to more fully understand the molecular basis of this 
disease, there is still an immediate need for accurate diagnoses of AD in living individuals.  In 
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addition, there is a need to monitor the progress of the disease in subjects that undergo treatment.  
With no current methods available to diagnose and monitor the progress of AD in living subjects 
with certainty, it is becoming increasingly important to identify key molecules integral to AD 
pathology that would make this possible.  In the absence of a unifying model of AD pathology, 
we can to turn to biomarker discovery methods such as those described in Chapter 2 in an effort 
to identify these key proteins.  These discovery methods do not require a full understanding of 
AD pathology and allow us to find correlation and potential biological patterns of interest in 
complex biological data sets that otherwise would be difficult, if not impossible, to detect. 
 
4.1 Future Directions 
Next steps for work described in Chapter 2 would be to obtain CSF specimens from a larger 
cohort of diseased and healthy individuals.  While the number of subjects considered in the 
analyses in Chapter 2 represents a large population in relative terms, as compared other AD 
studies of its kind, drawing conclusions from a larger pool of subjects may increase our overall 
confidence in obtained results.  Repeating similar analyses with a larger sample size, may 
improve the possibility of identifying biologically relevant proteins.  Additionally, with larger 
cohorts, it may be possible to identify a natural organization of expression patterns due to 
subpopulations that may exist within diseased subjects, allowing multiple mechanisms of 
pathology to be discovered. 
In Chapter 3, the iTRAQPak package was presented and its utility with iTRAQ 8-plex 
based protein expression data was demonstrated.  Since its introduction to the research 
community in the spring of 2008, there has been an immediate interest in this package.  This 
interest demonstrates the research community’s need for such an application, and further, it 
enables correspondence with users to identify potentially useful features that could be 
incorporated into future development efforts.  Correspondence with one user has revealed a 
desire to incorporate support for addition data import formats, beyond the currently supported 
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MascotGPS data format.  Suggestions for alternate format support included output generated by 
the software application ProteinPilot™ (ABI) and a more universal XML based format, 
pepXML. 
  iTRAQPak was developed in the R programming language.   While R is known to be a 
robust programming environment for the development of statistical and graphical applications, it 
can be somewhat daunting to those unfamiliar with this programming environment.  In an effort 
to offer iTRAQPak’s functionality in a more user friendly environment, future development 
could seek to incorporate elements of this package into a standalone environment based on 
programming languages such as JAVA or C++.  Such languages have the advantage of being 
more application centric and allow rich graphical user interfaces (GUI) to be developed.  Such an 
interface would allow data to be easily imported and saved in a manner that is familiar to most 
users.  In addition, the interface would allow a more interactive exploration of experimental data.  
For example, protein expression maps, instead of being static PDF images, could be displayed to 
allow such functionality as zooming, feature highlighting, expression pattern searches, and 
pattern clustering.  The environment could also allow data to be linked to web-based resources or 
local SQL databases for quick lookups of protein identities and function. Or, it could enable the 
storage of annotation and literature searches relating to expression profiles of interest.
  1 
APPENDIX 
ITRAQPAK SOURCE CODE 
 
 
LabelingEfficiency <- 
function( 
    file,  
    outfile="Efficiency.pdf" 
  ) 
{ 
  ## Load and transform data 
  idata <-  
    TransformData( 
      LoadData( 
        file,  
        mod.eval=T 
      ), 
      norm.method=0,  
      ratio=F,  
      LOG=F 
    ) 
   
  dat <- idata$DATA 
   
  ## Select dat subsets based on N or K labeled tag 
  datN1 <- dat[dat$N == 1,] 
  datN2 <- dat[dat$N == 2,] 
  datK1 <- dat[dat$K == 1,] 
  datK2 <- dat[dat$K == 2,] 
   
  ## Subset further 
  datN1K1 <- datN1[datN1$K == 1,] 
  datN1K2 <- datN1[datN1$K == 2,] 
  datN2K1 <- datN2[datN2$K == 1,] 
   
  ## Identify peptides that contain a K, but lack a K labeled tag 
  datKK2 <- datN1K2[grep("K", paste(datN1K2$Best.Peptide.Sequence)),] 
   
  ## Comine reshaped subsets into single data.frame 
  fsets <-  
    rbind( 
      data.frame( 
        reshape(datN1K1, idvar="id", varying=c(idata$COL.NAMES),  
          direction="long"), grp="Peptide Class: A" 
      ), 
      data.frame( 
        reshape(datN2K1, idvar="id", varying=c(idata$COL.NAMES),  
          direction="long"), grp="Peptide Class: B1" 
      ) 
    ) 
       
  fsets <- 
    rbind( 
      fsets, 
      data.frame( 
        reshape(datKK2, idvar="id", varying=c(idata$COL.NAMES),  
          direction="long"), grp="Peptide Class: B" 
      ) 
    ) 
 
  fsets <- 
    rbind( 
      fsets, 
      data.frame( 
        reshape(dat, idvar="id", varying=c(idata$COL.NAMES),  
          direction="long"), grp="Peptide Class: All" 
  2 
      ) 
    ) 
     
  fsets$grp <- factor(fsets$grp) 
  fsets$time <- factor(fsets$time) 
 
  ## Calculate total area of each subset 
  datKK2.sum <- colSums(datKK2[idata$COL.NAMES])   
  datN2K1.sum <- colSums(datN2K1[idata$COL.NAMES])   
  datN1K1.sum <- colSums(datN1K1[idata$COL.NAMES]) 
  dat.sum <- colSums(dat[idata$COL.NAMES]) 
    
  ## Calulate efficiency ratio: (B1 + B2) / A 
  eff.rats <-  
    data.frame( 
      Area=(datN2K1.sum + datKK2.sum)/datN1K1.sum,  
      id=names(datN2K1.sum), 
      grp="(B1 + B2) / A" 
    ) 
 
  ## Calulate efficiency ratio: B1 / A, bind to vals 
  eff.rats <- 
    rbind( 
      eff.rats,     
      data.frame( 
        Area=datN2K1.sum/datN1K1.sum,  
        id=names(datN2K1.sum), 
        grp="B1 / A" 
      ) 
    ) 
 
  ## Calulate efficiency ratio: B2 / A, bind to vals 
  eff.rats <- 
    rbind( 
      eff.rats, 
      data.frame( 
        Area=datKK2.sum/datN1K1.sum,  
        id=names(datKK2.sum), 
        grp="B2 / A" 
      ) 
    ) 
      
  ## Calculate sum of all peptide areas, scale to TAG[1] 
  eff.rats <- 
    rbind( 
      eff.rats, 
      data.frame( 
        Area = sumrat(dat.sum), 
        id=names(dat.sum), 
        grp="Total Area (Scaled to 113)" 
      ) 
    ) 
 
  eff.rats$grp <- factor(eff.rats$grp) 
 
  ## Create PDF file, 4 plots per page 
  pdf(file=outfile, width=8, height=8) 
  par(mfrow=c(2, 2))  
   
  ## Boxplots 
  bp <- bwplot( 
    log2(Area)~time | grp, 
    data=fsets, 
    as.table=T, 
    scales=list(x=list(rot=90)) 
  ) 
     
  print(update(bp, xlab="TAG")) 
   
  ## Barchart lattice, plots 5-8 
  b <-  
  3 
    barchart( 
      Area~id | grp,  
      data=eff.rats,  
      col="grey",  
      xlab="Ratio",  
      horizontal=F, 
      as.table=T, 
      main=NULL, 
      scales=list(x=list(labels=sub("Area.", "", levels(eff.rats$id)), rot=90)) 
    ) 
   
  print(update(b,xlab="TAG", ylab="%")) 
   
  quiet <- dev.off()  
} 
 
LabelingEfficiencyXY <- 
function( 
    file,  
    outfile="EfficiencyXY.pdf" 
  ) 
{ 
  col.fun <-   
    expression(  
      apply( 
        X,  
        MARGIN=1,  
        FUN = function(x){ 
          if( 
            (x["K"]==1 & x["N"]==2) | 
            (x["N"]==1 & x["K"]==2 & 
            any(grep("K", x["Best.Peptide.Sequence"])))         
          ) "red" else "black" 
        } 
      ) 
    ) 
   
  TagComparisonPlots(file=file, col.fun=col.fun, outfile=outfile) 
} 
 
LoadData <- 
function( 
    file,  
    rm.na=T,  
    mod.eval=F,  
    sep="\t", 
    tags.s1=c(113, 115, 117, 119), 
    tags.s2=c(114, 116, 118, 121) 
  ) 
{ 
  ## Assign columns to S1 and S2 given tag parameters  
  cols.s1 <-  
    sapply( 
      tags.s1,  
      FUN=function(x) paste("Area", x, sep=".") 
    ) 
 
  cols.s2 <-  
    sapply( 
      tags.s2,  
      FUN=function(x) paste("Area", x, sep=".") 
    ) 
   
  ## Read the data 
  dat <- read.table(file=file, sep=sep, header=T) 
   
  ## Remove rows w/ NA values 
  if(rm.na == T){ 
    dat <- dat[complete.cases(dat),] 
  } 
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  ## Rename lengthy column names 
  names(dat)[names(dat) == "Start.Sequence.Position"] <- "Start" 
  names(dat)[names(dat) == "End.Sequence.Position"] <- "Stop" 
   
  ## Create unique id column 
  dat <-  
    cbind( 
      id = c(1:dim(dat)[1]), 
      dat 
    ) 
   
  ## Order by start and stop 
  dat <- dat[order(dat$Start, dat$Stop),] 
   
  ## Evaluate secondary modifcations 
  if(mod.eval == T){ 
    dat <- addModCols(dat)                                   
  } 
   
  ## Set default expression heatmap highlight to black 
  dat$mod.col = 'black'                                
   
   
  ## Create idata 
  idata <-  
    list( 
      TAGS.S1 = tags.s1, 
      TAGS.S2 = tags.s2, 
      COLS.S1 = cols.s1, 
      COLS.S2 = cols.s2, 
      COL.NAMES = c(cols.s1, cols.s2), 
      DATA = dat 
    ) 
   
  return(idata) 
} 
 
PepMod <- 
function( 
  idata,  
  color="blue",  
  mod.ids=c("K","Y","N-term") 
 ){ 
   
  d <- idata$DATA 
   
  pep.cols <-  
    sapply(1:dim(d)[1], 
      function(x) 
        if(unlabeledSiteCount( 
              d[x,"Best.Peptide.Sequence"],  
              d[x,"Modification"], 
              mod.ids=mod.ids 
           ) > 0) 
          return("blue") 
        else 
          return("black") 
    ) 
     
  idata$DATA$mod.col <- pep.cols 
        
  return(idata) 
} 
 
PlotExpression <- 
function( 
    file=NULL, 
    idata=NULL, 
    outfile="gis.pdf", 
    gis="all", 
    sig.table=NULL, 
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    som.xdim=12, 
    som.ydim=15, 
    topol="rect", 
    neigh="bubble", 
    radius=3, 
    alpha=0.05, 
    match.types=0, 
    trend=NULL, 
    pwidth=15, 
    append.output=T 
  ) 
{ 
   
  ## Check Trend Input 
  if(any(2 == match.types) & is.null(trend)){ 
    e <- simpleError( 
          paste("SOM trend matching specified without trend object.", 
                "(match.types=2, trend=NULL) ")) 
    stop(e) 
  }else if(any(3 == match.types) & is.null(trend)){ 
    e <- simpleError( 
          paste("Trend matching specified without trend object.", 
                "(match.types=3, trend=NULL) ")) 
    stop(e) 
  } 
 
  ## Load and transform data to package default 
  if(is.null(idata)){ 
    idata <- TransformData(LoadData(file)) 
  } 
     
  ## Count number of gis 
  if(gis[1] == 'all'){ 
    gis <- levels(idata$DATA$Accession.Number) 
  }else{ 
    gis <- levels(factor(gis)) 
  } 
   
  ## Train SOM 
  som.train <- trainSom(idata, som.xdim, som.ydim) 
   
  ## Draw maps, one for each GI 
  for(i in 1:length(gis)){ 
     
    if(sum(match.types) > 0){ 
      match.types <- c(0, match.types) 
    } 
     
    ## Assign output name, conditionally 
    if(append.output == F){ 
      outfile = paste(sub("\\|", ".", gis[i]), ".pdf", sep="") 
    } 
 
    ## Make a map for each match.type 
    for(match.type in match.types){ 
 
      if(names(dev.cur()) != "pdf"){ 
        pdf(file=outfile, height=10, width=pwidth, pointsize=12) 
      } 
 
      draw( 
        idata,  
        gi=gis[i],  
        som.train=som.train,  
        match.type=match.type,  
        sig.table=sig.table, 
        pwidth=pwidth, 
        trend=trend 
      ) 
 
      ## Close the outfile if not appending, suppress output 
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      if(append.output==F){ 
        quiet <- dev.off() 
      } 
    } 
  } 
 
  ## Insure pdf device is closed 
  if(names(dev.cur()) == "pdf"){ 
    quiet <- dev.off() 
  } 
} 
 
TagComparisonPlot <- 
function(   
    idata, 
    x.col,  
    y.col, 
    col=1, 
    main 
  ) 
{ 
 
  dat <- idata$DATA 
 
  xlab <- x.col 
  ylab <- y.col 
  dat.xy <- cbind(dat[, x.col], dat[, y.col]) 
  xy.max <- max(dat.xy) 
  xy.min <- min(dat.xy) 
 
  plot( 
    dat[, x.col],  
    dat[, y.col], 
    las=2, 
    main = main, 
    cex.main=.85, 
    xlim = c(xy.min, xy.max), 
    ylim = c(xy.min, xy.max), 
    col = col, 
    xlab = xlab, 
    ylab = ylab 
  ) 
 
  xy.max.c <- ceiling(xy.max) 
  xy.min.f <- floor(xy.min) 
  lines(c(xy.min.f, xy.max.c), c(xy.min.f, xy.max.c)) 
} 
 
TagComparisonPlots <- 
function( 
    file=NULL, 
    idata=NULL, 
    rm.na=T,  
    sep="\t", 
    correct=F, 
    norm.method=0, 
    LOG=T, 
    col="black", 
    col.fun=NULL, 
    outfile="TagComparison.pdf", 
    tags.s1=c(113, 115, 117, 119), 
    tags.s2=c(114, 116, 118, 121) 
  ) 
{   
 
  ## Load and transform data 
  if(!is.null(file) & is.null(idata)){ 
    idata <-  
      TransformData( 
        LoadData( 
          file, 
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          rm.na=T, 
          mod.eval=T, 
          sep="\t", 
          tags.s1=tags.s1, 
          tags.s2=tags.s2 
        ), 
        correct=correct, 
        norm.method=norm.method,  
        ratio=F,  
        LOG=T 
      ) 
  } 
       
  ## Apply coloring via function if supplied  
  if(!is.null(col.fun)){ 
    X <- idata$DATA 
    col <- eval(expr=col.fun, envir=X) 
  } 
   
  ## Plot images to PDF 
  pdf(outfile, height=8, width=8) 
    
  for(j in 1:2){ 
    par(mfrow=c(2, 2))  
    if(j == 1) cols <- idata$COLS.S1 else cols <- idata$COLS.S2 
    for(i in 1:4){ 
     TagComparisonPlot( 
        idata, 
        cols[1],  
        cols[i], 
        col=col, 
        paste(cols[1], cols[i], sep=" x ") 
      ) 
    } 
  } 
   
  quiet <- dev.off() 
} 
 
TagSummaryBoxPlot <- 
function(file, sep="\t", outfile="TagSummary.pdf"){ 
 
  idata <-  
    LoadData( 
      file, 
      rm.na=T, 
      mod.eval=F, 
      sep=sep 
    ) 
 
  pdf(file=outfile, height=10, width=14, pointsize=12) 
 
  ## log2, uncorrected unnormalized raw 
  idata1 <- TransformData(idata, correct=F, LOG2=T, ratio=F, norm.method=0) 
   
  ## log2, uncorrected unnormalized ratio 
  idata2 <-  
    TransformData(idata, correct=F, LOG2=T, ratio=T, norm.method=0) 
 
  ## log2, corrected median normalized ratio 
  idata3 <-  
    TransformData(idata, correct=T, LOG2=T, ratio=T, norm.method=1) 
   
  ## log2, corrected mean normalized ratio 
  idata4 <-  
    TransformData(idata, correct=T, LOG2=T, ratio=T, norm.method=2) 
   
  ## log2, corrected lowess normalized ratio 
  idata5 <-  
    TransformData(idata, correct=T, LOG2=T, ratio=T, norm.method=3) 
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  ## log2, corrected lowess normalized ratio 
  idata6 <-  
    TransformData(idata, correct=T, LOG2=F, ratio=F, norm.method=3) 
   
  ## Generate BoxPlots 
  par(mfrow=c(2, 3)) 
 
  boxplot( 
    idata1$DATA[,idata1$COL.NAMES],  
    las=2, 
    main = "Uncorrected, Unnormalized, LOG2", 
    cex.main=.85 
  ) 
   
  boxplot( 
    idata2$DATA[,idata2$COL.NAMES],  
    las=2,  
    main = "Uncorrected, Unnormalized, Ratio, LOG2",  
    cex.main=.85 
  ) 
   
  boxplot( 
    idata3$DATA[,idata3$COL.NAMES],  
    las=2,  
    main = "Corrected, Median Normalized, Ratio, LOG2",  
    cex.main=.85 
  ) 
 
  boxplot( 
    idata4$DATA[,idata4$COL.NAMES],  
    las=2,  
    main = "Corrected, Mean Normalized, Ratio, LOG2",  
    cex.main=.85 
  ) 
 
  boxplot( 
    idata5$DATA[,idata5$COL.NAMES],  
    las=2, 
    main = "Corrected, LOWESS Normalized, Ratio, LOG2",  
    cex.main=.85 
  ) 
   
  quiet <- dev.off() 
} 
 
TransformData <- 
function( 
    idata,  
    correct=T,  
    LOG2=T,  
    ratio=T, 
    norm.method=1, 
    dat.subset=NULL, 
    rm.na=T, 
    cf.table=NULL 
  ) 
{ 
   
  ## Correct for carryover between peaks 
  if(correct){ 
     
    ## Use default correction values if cf.table is NULL 
    if(!is.null(cf.table)){  
      CF.TABLE <- cf.table 
    } 
     
    ## Correct area values 
    idata$DATA[,idata$COL.NAMES] <- 
      correct( 
        idata$DATA[,idata$COL.NAMES],  
        c(idata$ISO.S1, idata$ISO.S2), 
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        CF.TABLE 
      ) 
  } 
   
  ## [OPTION 1]  Median, all to S1 (t0) 
  if(norm.method == 1){                
    idata$DATA[,idata$COL.NAMES] <-  
      normMedian(idata$DATA[,idata$COL.NAMES]) 
  ## [OPTION 2]  Mean, all to S1 (t0) 
  }else if(norm.method == 2){          
    idata$DATA[,idata$COL.NAMES] <-  
      normMean(idata$DATA[,idata$COL.NAMES]) 
  ## [OPTION 3]  LOWESS 
  }else if(norm.method == 3){         
    idata$DATA[,idata$COL.NAMES] <-  
      normLowess(idata$DATA[,idata$COL.NAMES]) 
  ## [OPTION 4]  Median, to S1 and S2 (t0) 
  }else if(norm.method == 4){          
    idata$DATA[,idata$COLS.S1] <-  
      normMedian(idata$DATA[,idata$COLS.S1]) 
    idata$DATA[,idata$COLS.S2] <-  
      normMedian(idata$DATA[,idata$COLS.S2]) 
  ## [OPTION 5]  Median, to subset, to S1 (t0) 
  }else if(norm.method == 5){         
    idata$DATA[,idata$COL.NAMES] <-  
      normMedianSubset( 
        idata$DATA[,idata$COL.NAMES],  
        dat.subset[,idata$COL.NAMES] 
      ) 
  } 
 
  ## RATIO       
  if(ratio){ 
    idata$DATA[,idata$COLS.S1] <- ratio(idata$DATA[,idata$COLS.S1]) 
    idata$DATA[,idata$COLS.S2] <- ratio(idata$DATA[,idata$COLS.S2]) 
  } 
   
  ## LOG2 Transformation 
  if(LOG2){ 
    idata$DATA[,idata$COL.NAMES] <- log2(idata$DATA[,idata$COL.NAMES]) 
  } 
   
  ## Remove NA values 
  #dat <- dat[complete.cases(dat),] 
  if(rm.na){ 
    idata$DATA  <- IDPmisc::NaRV.omit(idata$DATA) 
  } 
   
  return(idata) 
} 
 
addModCols <- 
function(dat){ 
 
  dat[grep("Oxidation", paste(dat$Modification)), "O"] <- 1 
  dat[grep("MMTS", paste(dat$Modification)), "M"] <- 1 
  dat[grep("\\(N-term\\)\\[0\\]", paste(dat$Modification)), "N"] <- 1 
  dat[grep("8plex \\(K\\)", paste(dat$Modification)), "K"] <- 1 
  dat[grep("8plex \\(Y\\)", paste(dat$Modification)), "Y"] <- 1 
   
  if(length(dat[is.na(dat)]) > 1){ 
    dat[is.na(dat)] <- 2   
  } 
   
  return(dat) 
} 
 
addSigValues <- 
function(sc, sig.table, col.name, ymin.global){ 
 
  peptides <- levels(factor(sc$peptide)) 
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  for(i in 1:length(peptides)){ 
   
    peptide <- peptides[i] 
 
    sigVal <- sig.table[sig.table$Peptide == peptide, col.name][1] 
       
    if(!is.na(sigVal)){ 
       
      x <- sc[sc$peptide == peptide, "x"][1] 
 
      text(x, ymin.global + 0.5, format(sigVal, digits=4), cex=.7, 
           pos=4, srt=90) 
    } 
  } 
} 
 
as.trend <- 
function(s){ 
  return(parse(text=gsub("[Tt]", "V", x=s))) 
} 
 
colorize <- 
function(x){ 
 
  ## Set.max.val, let min max.val = 1 
  max.val <- ceiling(max(abs(x))) 
 
  y <- sapply( 
        x,  
        FUN = function(x)  
                ifelse( 
                  x > 0, 
                  (x/max.val) * 100 / 2 + 50, 
                  (1-abs(x/max.val)) * 100 / 2 
                )  
        ) 
         
  ## Zero not a color 
  ## Let zero values = 0.001 
  y[y==0] <- 0.001 
 
  return(y) 
} 
 
correct <- 
function(x, tags, cf.table){ 
 
  for(i in tags){ 
     
    ## Assign column name 
    col.name <- paste("Area.", i, sep="") 
     
    ## Get corection factor 
    cf <- (correctionFactor(i, cf.table)/100) 
     
    x[, col.name] <-  x[, col.name] - (x[,col.name] * cf) 
  } 
   
  return(x) 
} 
 
correctionFactor <- 
function(tag, cf.table){ 
   
  tags <- c(113, 114, 115, 116, 117, 118, 119, 121) 
  correction.factors <- cf.table 
   
  cf = 0 
   
  for(i in c(-2,-1,1,2)){ 
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    if(tag - i >= min(tags) & tag + i <= max(tags)){ 
      cf.val <- correction.factors[paste(tag + i), getCol(i)] 
      if(!is.na(cf.val)){ 
        cf <- (cf + cf.val) 
      } 
    } 
  } 
  return(cf) 
} 
 
draw <- 
function( 
    idata,  
    gi,  
    som.train,  
    match.type, 
    sig.table, 
    pwidth, 
    trend 
  ) 
{ 
   
  ## Get DATA from idata 
  dat <- idata$DATA 
   
  ## Set output ajustment parameters for plots  
  vadj.d <- -0.4 
  vadj.a <- .273 
 
  palette("default")  
   
  ## Get the protein name 
  name <- paste(dat[dat$Accession.Number == gi, "Protein.Name"][1]) 
   
  ## Draw plots 
  drawBasePlot(gi, name) 
  drawLines(dat, gi, som.train, match.type, sig.table, idata$COLS.S1,  
            idata$COLS.S2, idata$COL.NAMES, trend, pwidth) 
  drawAverageLines(dat, gi, vadj.a, sig.table, idata$COL.NAMES, pwidth) 
  drawPeptides(dat, gi, idata$COL.NAMES, pwidth) 
  drawAverageAllLines(dat, gi, idata$COLS.S1, idata$COL.NAMES, 1.78) 
  drawAverageAllLines(dat, gi, idata$COLS.S2, idata$COL.NAMES, 1.295) 
} 
 
drawAverageAllLines <- 
function(dat, gi, cols.subj, col.names, vadj){ 
 
  #get Y min/max .global 
  ymin.global <- min(dat[,col.names]) 
  ymax.global <- max(dat[,col.names]) 
 
  #get only row w/ gi of interest 
  dat <- dat[dat$Accession.Number == gi,] 
 
  #calculate mean of each timepoint 
  dat.m <-  
    sapply( 
      cols.subj,  
      FUN = function(x) apply(t(dat[,x]), 1, mean) 
    ) 
   
  #make plotable 
  sc <- data.frame(x=c(1,2,3,4), y=dat.m) 
   
  subplot( 
    plot( 
      sc$x,  
      sc$y,  
      #ylim = c(min(sc$y), max(sc$y)),  
      ylim = c(ymin.global, ymax.global), 
  12 
      xlim = c(0, 5),  
      type="l", 
      ylab = "", 
      xlab = "", 
      xaxt = "n", 
      yaxt = "n", 
      cex.axis = .75 
    ), 
    -.085, 
    vadj, 
    size=c(1, 1.8), 
    vadj=1, 
    hadj=0 
  ) 
} 
 
drawAverageLines <- 
function(dat, gi, vadj, sig.table, col.names, pwidth){ 
 
  ## Get Y min/max .global 
  ymin.global <- min(dat[,col.names]) 
  ymax.global <- max(dat[,col.names]) 
 
  ## Get only row with GI of interest 
  dat <- dat[dat$Accession.Number == gi,] 
  dat$Best.Peptide.Sequence <-  
    dat$Best.Peptide.Sequence[drop = TRUE] 
 
  dat <-  
    cbind( 
      dat,  
      id2=factor(as.numeric(paste(dat$Start, dat$Stop, sep="."))), 
      ordered=T 
    ) 
 
  dat.f1<-  
    sapply( 
      col.names,  
      FUN = function(x) tapply(dat[,x], factor(dat$id2), mean) 
    ) 
 
  dat.coords.start <- 
    sapply( 
      unique(factor(dat$id2)),  
      FUN = function(x) dat[dat$id2 == x , "Start"][1] 
    ) 
     
  dat.coords.stop <- 
    sapply( 
      unique(factor(dat$id2)),  
      FUN = function(x) dat[dat$id2 == x , "Stop"][1] 
    ) 
     
  dat.peptides <- 
    sapply( 
      unique(factor(dat$id2)),  
      FUN = function(x) paste(dat[dat$id2 == x , "Best.Peptide.Sequence"][1]) 
  ) 
 
  dat.f2 <-  
    data.frame( 
      Start=dat.coords.start, 
      Stop=dat.coords.stop, 
      t = rbind(dat.f1),  
      peptide = dat.peptides 
    ) 
 
  sc.1 <-  
    getLines( 
      dat.f2[,"Start"],  
      dat.f2[,"Stop"],  
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      dat.f2[,3:6],                    
      0,  
      rep(1, dim(dat.f2)[1]), 
      peptide=dat.f2[,"peptide"] 
    ) 
   
  sc.2 <-  
    getLines( 
      dat.f2[,"Start"],  
      dat.f2[,"Stop"],  
      dat.f2[,7:10],                     
      0,  
      rep(1, dim(dat.f2)[1]), 
      peptide=dat.f2[,"peptide"] 
    ) 
   
  ## Set X max 
  if(max(sc.1$x) <= 300) 
    xmax.local <- 300 
  else 
    xmax.local <- max(sc.1$x) 
   
  ## Set color palette 
  palette("default") 
   
  sp.a <- subplot( 
    plot( 
      0,  
      0,   
      ylim = c(ymin.global, ymax.global), 
      xlim = c(-25, xmax.local),  
      type="n", 
      ylab = "Average Ratio", 
      xlab = "", 
      xaxt = "n", 
    ), 
    -.085, 
    2.4, 
    size=c(pwidth -1, 1.8), 
    vadj=1 + vadj,  
    hadj=0 
  ) 
   
  ## Prepare graphics, plot lines within subplot sp.l  
  op <- par(no.readonly=TRUE) 
  par(sp.a) 
   
  for(i in 1:nlevels(factor(sc.1$group))){     
    lines(sc.1[sc.1$group==i,]$x, sc.1[sc.1$group==i,]$y, col=1) 
    lines(sc.2[sc.2$group==i,]$x, sc.2[sc.2$group==i,]$y, col=2) 
  } 
   
  if(!is.null(sig.table)) 
    addSigValues(sc.1, sig.table, "Both", ymin.global) 
 
  par(op) 
} 
 
drawBasePlot <- 
function(gi, name){ 
     
  plot( 
    0, 
    0,  
    xlim=c(0,2),  
    ylim=c(0,2),  
    frame.plot=F,  
    yaxt = "n",  
    xaxt = "n",  
    ylab="",  
    xlab="",  
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    type="n" 
  ) 
   
  text(-.08,.77, paste(gi, name, sep=" "), pos=4, cex=.85) 
} 
 
drawColorScale <- 
function(pos.x, pos.y, min.exp, max.exp){ 
 
  min.exp <- format(min.exp, digits=2) 
  max.exp <- format(max.exp, digits=2) 
 
  y <- c(0:10)/20 
  color <- c(0:10) * 10 + .01 
   
  rect( 
    pos.x,  
    pos.y + y,  
    pos.x + 0.025,  
    pos.y + y + 0.05,  
    col=color 
  ) 
   
  ## Add scale labels 
  text(pos.x -0.03, pos.y + 0.02, min.exp, cex=0.75) 
  text(pos.x -0.03, pos.y + 0.02 + .5, max.exp, cex=0.75) 
} 
 
drawLines <- 
function( 
    dat,  
    gi,  
    som.train,  
    match.type=0,  
    sig.table, 
    cols.s1, 
    cols.s2, 
    col.names, 
    trend, 
    pwidth 
  ) 
{ 
 
  som.colors.1 <- NULL 
  som.colors.2 <- NULL 
 
  ## Current default: set min max based on protein 
  global.color.scale = F 
 
  ## Get only row w/ gi of interest 
  datg <- dat[dat$Accession.Number == gi,] 
   
  ## Set color scale Y min/max .global 
  ymin.global <- min(dat[,col.names]) 
  ymax.global <- max(dat[,col.names]) 
 
  ## Get the SOM, if there is more than one peptide 
  if(dim(datg)[1] > 1){ 
    r.som.1 <- testSom(som.train, exp.vals = datg[,cols.s1]) 
    r.som.2 <- testSom(som.train, exp.vals = datg[,cols.s2]) 
    som.id.1 <- r.som.1$id 
    som.id.2 <- r.som.2$id 
  }else{ 
    som.id.1 <- 1  
    som.id.2 <- 1 
  } 
     
  ## Set SOM color palette 
  ## Cacluate color range from size of SOM grid 
  ## Palette(rainbow(100, start=0, end=2/6)) 
  color.range <- som.train$xdim * som.train$ydim 
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  palette(rainbow(color.range, start=.18, end=.15)) 
       
  sc <-          
    getLines2( 
      datg[,"id"], 
      datg[,"Start"],  
      datg[,"Stop"],  
      datg[,col.names],  
      som.id.1,  
      som.id.2, 
      peptide=datg[,"Best.Peptide.Sequence"] 
    ) 
      
  ## Determine match.type, get trends accordingly 
  if(match.type == 1)         trends <- NULL 
  else if(match.type == 2)    trends <- getSomTrends(som.train, trend) 
  else if(match.type == 3)    trends <- findTrends(datg, trend, cols.s1, cols.s2) 
   
   
   
  ## Highlight matches 
  if(match.type > 0){  
    #write.table(trends, file="trends2.txt") 
    sc <- highlightLines(sc, match.type, trends) 
  } 
   
  ## Set X max 
  if(max(sc$x) <= 300) 
    xmax.local <- 300 
  else 
    xmax.local <- max(sc$x) 
 
  ## Plot Subject 1 (upper plot) 
  sp.u <- subplot( 
    plot( 
      0, 
      0, 
      ylim = c(ymin.global, ymax.global), 
      xlim = c(-25, xmax.local),  
      type="n", 
      ylab = "Peak Area (log2 ratio)", 
      xlab = "", 
      xaxt = "n", 
    ), 
    -.085, 
    1.78, 
    size=c(pwidth-1, 1.8), 
    vadj=1,  
    hadj=0 
  ) 
     
  ## Plot Subject 2 (lower plot)   
  sp.l <- subplot( 
    plot( 
      0, 
      0,  
      ylim = c(ymin.global, ymax.global), 
      xlim = c(-25, xmax.local),  
      type="n", 
      ylab = "Peak Area (log2 ratio)", 
      xlab = "", 
      xaxt = "n", 
    ), 
    -.085, 
    1.295, 
    size=c(pwidth-1, 1.8), 
    vadj=1,  
    hadj=0 
  ) 
   
  ## Prepare graphics, plot lines within subplot sp.l  
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  op <- par(no.readonly=TRUE) 
   
  ## Order so colored highlights are on top 
  sc <- sc[order(sc$s1.hl),]  
 
  ## Plot lines for Subject 1 
  for(i in unique(factor(sc$group))){ 
   
    col.s1 <- sc[sc$group==i, "s1.id"][1] 
 
    if(match.type > 0 && sc[sc$group==i, "s1.hl"][1] == FALSE) 
      col.s1 <- "grey" 
     
    ## Plot Subject 1 (upper plot) 
    par(sp.u) 
    lines( 
      sc[sc$group==i,]$x,  
      sc[sc$group==i,]$y.s1,  
      col=paste(col.s1) 
    ) 
  } 
   
  ## Add significance values if supplied 
  if(!is.null(sig.table)) 
      addSigValues(sc, sig.table, "S1", ymin.global) 
   
  sc <- sc[order(sc$s2.hl),]  
   
  ## Plot lines for Subject  2 
  for(i in unique(factor(sc$group))){ 
 
    col.s2 <- sc[sc$group==i, "s2.id"][1] 
 
    if(match.type > 0 && sc[sc$group==i, "s2.hl"][1] == FALSE) 
      col.s2 <- "grey" 
 
    ## Lower plot 
    par(sp.l) 
    lines( 
      sc[sc$group==i,]$x,  
      sc[sc$group==i,]$y.s2,  
      col=paste(col.s2) 
    )        
  } 
   
  if(!is.null(sig.table)) 
    addSigValues(sc, sig.table, "S2", ymin.global) 
 
  par(op) 
} 
 
drawPeptides <- 
function(dat, gi, col.names, pwidth){ 
 
  ## Default level 
  level.base <- .15 
  level <- level.base 
  max.levels <- 0 
 
  ## Set color palette (red, yellow, green) 
  palette(rainbow(100, start=0, end=2/6)) 
   
  dat.gi <- dat[dat$Accession.Number == gi,] 
  dat.colors = dat.gi 
  dat.colors[,col.names] <- colorize(dat.gi[,col.names]) 
   
  ## Set X max 
  if(max(dat.gi$Stop) <= 300) 
    xmax.local <- 300 
  else 
    xmax.local <- max(dat.gi$Stop) 
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  ## Set max pep levels 
  max.pep.levels <- getMaxPepLevels(dat.gi) 
 
  ## Create peptide plot area 
  sp.p <- subplot( 
    plot( 
      0,  
      0,  
      ylim = c(.25, 11), 
      xlim = c(-25, xmax.local),  
      type="n", 
      ylab = "", 
      xlab = "", 
      yaxt = "n", 
      omi = c(0,0,0,0) 
    ), 
    -.085, 
    -.25, 
    size=c(pwidth-1, 4), 
    vadj=0,  
    hadj=0 
  ) 
 
  ## Prepare graphics, plot lines within subplot sp.p  
  op <- par(no.readonly=TRUE) 
  par(sp.p) 
   
  for(i in 1:dim(dat.gi)[1]){ 
 
    ## Increment rectangle levels, avoid overlap 
    if(overlaps(dat.gi, i)){ 
      level <- (level + .4) 
    }else{ 
      level <- level.base 
    } 
 
    r <-  
      getRectangle( 
        dat.gi[i,"Start"],  
        dat.gi[i,"Stop"],  
        level, 
        as.vector(dat.colors[i, col.names], mode="numeric"), 
        dat.gi[i, "mod.col"] 
      ) 
 
    rect(r$xl, r$yb, r$xr, r$yt, col=r$exp.vals, border=paste(r$mod.col)) 
  } 
 
  par(op) 
   
  ## Draw color scale, assumes min/max set 
  ## relative to protein, not global, 
  ## see colorize function 
  max.val <- ceiling(max(abs(dat.gi[,col.names]))) 
  drawColorScale(-.01, 0, -1 * max.val, max.val) 
} 
 
findTrends <- 
function(dat, trend, cols.s1, cols.s2){ 
 
  #Rename to generic column names: Subject 1 
  x <- dat[c(cols.s1, cols.s2)] 
  names(x) <- rep(c("V1", "V2", "V3", "V4"), 2) 
   
  #Evauluate trends 
  s1 <- row.names(x[eval(trend, envir=x[1:4]),]) 
  s2 <- row.names(x[eval(trend, envir=x[5:8]),]) 
  
  y <- list(s1=as.vector(c(s1)), s2=as.vector(c(s2))) 
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  return(y) 
} 
 
getCol <- 
function(x){   
  if(x == -2)       return(4) 
  else if(x == -1)  return(3) 
  else if(x == 1)   return(2) 
  else if(x == 2)   return(1) 
} 
 
getLines <- 
function(start, stop, exp.vals, yshift, som.colors, peptide){ 
   
  x1 <-  
    apply( 
      array(1:3),  
      1,  
      FUN = function(x) start + ((stop - start)/3) * x 
    ) 
  x1 <- cbind(start, rbind(x1)) 
  x2 <- data.frame(NULL) 
   
  for(i in 1:length(start)){ 
   
    e1 <- data.frame(t(exp.vals[i,])) 
    e1 <- e1 + yshift 
    names(e1)[1]<- "y" 
    x2 <-  
      rbind( 
        x2,  
        data.frame( 
          group=i,  
          x=x1[i,],  
          e1,  
          somColor=som.colors[i],  
          peptide[i] 
        ) 
      ) 
  } 
   
  row.names(x2) <- c(1:dim(x2)[1]) 
   
  return(x2) 
} 
 
getLines2 <- 
function( 
    ids,  
    start,  
    stop,  
    exp.vals,  
    s1.ids,  
    s2.ids,  
    peptide 
  ) 
{ 
   
  ## Create start/stop array 
  x1 <-  
    apply( 
      array(1:3),  
      1,  
      FUN = function(x) start + ((stop - start)/3) * x 
    ) 
  x1 <- cbind(start, rbind(x1))  
  x <- data.frame(NULL) 
   
  for(i in 1:length(start)){ 
   
    s1.exp <- data.frame(t(exp.vals[i,1:4]))  
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    s2.exp <- data.frame(t(exp.vals[i,5:8]))  
    names(s1.exp)[1]<- "y.s1" 
    names(s2.exp)[1]<- "y.s2" 
         
    ## Set line features, note hl (highlight) default = T 
    x <-  
      rbind( 
        x,  
        data.frame( 
          id = ids[i], 
          group=i,  
          x=x1[i,],  
          s1.exp,  
          s2.exp,  
          s1.id=s1.ids[i],  
          s2.id=s2.ids[i], 
          s1.hl = TRUE, 
          s2.hl = TRUE, 
          peptide = peptide[i] 
        ) 
      ) 
  } 
   
  row.names(x) <- c(1:dim(x)[1]) 
   
  return(x) 
} 
 
getMaxPepLevels <- 
function(dat){ 
 
  pep.levels <- 0 
  max.pep.levels <- 0 
   
  for(i in 1:dim(dat)[1]){ 
    if(overlaps(dat, i)){ 
        pep.levels <- pep.levels + 1 
    }else{ 
      if(pep.levels > max.pep.levels){ 
        max.pep.levels <- pep.levels 
      } 
      pep.levels <- 0 
    } 
  } 
   
  return(max.pep.levels) 
} 
 
getRectangle <- 
function(start, stop, level, exp.vals, mod.col){ 
 
  x1 <-  
    apply( 
      array(1:4),  
      1,  
      FUN = function(x) start + ((stop - start)/4) * x 
    ) 
  x1 <- cbind(start, t(x1)) 
   
  x2 <-  
    rbind( 
      cbind(x1[1], x1[2]), 
      cbind(x1[2], x1[3]), 
      cbind(x1[3], x1[4]), 
      cbind(x1[4], x1[5]) 
    ) 
  x2 <- data.frame(x2); names(x2) <- c("xl", "xr") 
   
  #top rectangle (subject 1) 
  x3 <- cbind(x2, yb = level) 
  x3 <- cbind(x3, yt = level + .15) 
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  #bot rectangle (subject 2), duplicate x3, shift lower rec by -.15 
  x4 <- rbind(x3, x3) 
  x4[5:8, c("yb", "yt")] <-  x4[5:8, c("yb", "yt")] - .15 
   
  x5 <- cbind(x4, exp.vals); names(x5)[5] <- "exp.vals" 
  x6 <- cbind(x5, mod.col); names(x6)[6] <- "mod.col" 
   
  return(x6) 
} 
 
getSomColors <- 
function(som.train, som.proj){ 
 
  sp <-  
    cbind( 
      som.proj,  
      xy = paste(som.proj$x, som.proj$y, sep=".") 
    ) 
   
  st <-  
    cbind( 
      som.train$code.sum,  
      xy = paste(som.train$code.sum$x, som.train$code.sum$y, sep="."), 
      id = as.numeric(row.names(som.train$code.sum)) 
    ) 
       
  sp$row.order = row.names(sp) 
  ids <- merge(st, sp) 
 ids <- ids[order(ids$row.order),][1:6] 
   
  return(ids)  
} 
 
getSomTrends <- 
function(som.train, trend){ 
 
  x <-  
    data.frame( 
      as.data.frame(som.train$code),  
      som.id = c(1:dim(as.data.frame(som.train$code))[1]) 
    ) 
     
  y <- x[eval(expr=trend, envir=x), "som.id"] 
                 
  return(y) 
} 
 
highlightLines <- 
function(x, type, ids){ 
 
  if(type == 1){ 
   
    x[,"s2.hl"] <- x[,"s1.hl"] <-  
      apply( 
        x,  
        1,  
        FUN=function(x) if(x["s1.id"] == x["s2.id"]) T else F 
      ) 
         
  }else if(type == 2){ 
   
    x[,"s1.hl"] <-  
      apply( 
        x,  
        1,  
        FUN=function(x) if(any(x["s1.id"] == ids)) T else F 
      ) 
    x[,"s2.hl"] <-  
      apply( 
        x,  
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        1,  
        FUN=function(x) if(any(x["s2.id"] == ids)) T else F 
      ) 
   
  }else if(type == 3){ 
     
    x[,"s1.hl"] <-  
      apply( 
        x,  
        1,  
        FUN=function(x) if(any(x["id"] == ids$s1)) T else F 
      ) 
    x[,"s2.hl"] <-  
      apply( 
        x,  
        1,  
        FUN=function(x) if(any(x["id"] == ids$s2)) T else F 
      ) 
  } 
     
  return(x) 
} 
 
isSig <- 
function(pvals, cuttoff=0.05){ 
 
  sig <- pvals[!is.na(pvals$S1) & pvals$S1 < cuttoff &  
               pvals$S2 < cuttoff & pvals$Both > cuttoff,] 
  return(sig) 
} 
 
lmePeptide <- 
function(x){ 
  
  ## Set default values 
  anova.s1 <- anova.s2 <- anova.all <- data.frame(p=c(NA, NA, NA)) 
 
  x$Time <- factor(x$Time) 
  x$id <- paste(x$id, x$Subject, sep="_") 
  x$id <- factor(x$id) 
  x$Subject <- factor(x$Subject) 
 
  ## Create LME Grouping 
  x.group <- groupedData(Area ~ Time | id, data=x) 
     
  ## Determine number of observations 
  n <- nlevels(factor(x$id)) 
 
  ## Perform LME analysis 
  if(n >= 4){         
    try(lme.all <- lme(Area ~ Time * Subject, random = ~1|id, data=x.group)) 
    anova.all <- anova(lme.all) 
  } 
 
  if(n >= 4){ 
    try(lme.s1 <- lme(Area ~ Time, random = ~1|id, subset= Subject == 1,  
                      data=x.group))    
 
    try(lme.s2 <- lme(Area ~ Time, random = ~1|id, subset= Subject == 2, 
                      data=x.group)) 
 
    anova.s1 <- anova(lme.s1) 
    anova.s2 <- anova(lme.s2) 
  } 
 
  ## Create data.frame of p-values 
  pvals <-  
    data.frame( 
      id=x[, "id"][1], 
      Peptide=x[, "Peptide"][1], 
      Name=x[, "Name"][1], 
  22 
      GI=x[, "GI"][1], 
      n=n, 
      S1=anova.s1$p[2], 
      S2=anova.s2$p[2], 
      Both=anova.all$p[4] 
    ) 
 
  return(pvals) 
} 
 
LMEPeptide <- 
function(idata){ 
 
  ## Reshape data, wide to long 
  idata <- reshapeData(idata) 
   
  ## LME: call lmePeptide for each level of dat$Peptide 
  pvals <- gapply(idata$DATA.LONG, form=Area~Peptide, level="Peptide",  
                  FUN=lmePeptide) 
   
  ## Stack pvals, convert to data.frame 
  pvals <- as.data.frame(do.call("rbind", pvals)) 
 
  ## Order by significance 
  pvals.ordered <- pvals[order(pvals$Both),] 
   
  return(pvals.ordered) 
} 
 
modCount <- 
function(mod, mod.string){ 
  mval <- regexval(paste("\\(", mod,"\\).*?\\]", sep=""), as.character(mod.string)) 
  x <- length(strsplit(substring(mval, 5, nchar(mval)-1), ",")[[1]]) 
  return(x) 
} 
 
normLowess <- 
function(x){ 
 
  x <- LPE::preprocess(x, data.type="MAS5", LOWESS = T) 
 
  # non-log2 
  x <- 2^x 
   
  return(x) 
} 
 
normMean <- 
function(x, trim=0.05){ 
 
  for(i in 2:dim(x)[2]){   
    x[,i] <- x[, i] * (mean(x[, 1], trim=trim) / mean(x[, i], trim=trim)) 
  } 
 
  return(x) 
} 
 
normMedian <- 
function(x){ 
 
  for(i in 2:dim(x)[2]){   
    x[,i] <- x[, i] * (median(x[, 1]) / median(x[, i])) 
  } 
 
  return(x) 
} 
 
normMedianSubset <- 
function(x, x.subset){ 
 
  for(i in 2:dim(x)[2]){   
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    x[,i] <- x[, i] * (median(x.subset[, 1]) / median(x.subset[, i])) 
  } 
 
  return(x) 
} 
 
overlaps <- 
function(dat, iq){ 
 
  ## Assign start stop values for ith peptide (iq == i) 
  s1 <- dat[iq,"Start"] 
  s2 <- dat[iq,"Stop"] 
 
  ol <- FALSE 
  i <- 1 
   
  ## Check for overlap 
  while(!ol & i < dim(dat)[1] & i < iq){ 
     
    sp <- dat[i,"Stop"] 
    st <- dat[i,"Start"] 
     
    if(s1 <= sp &&  s2 >= st){ 
      ol <- TRUE 
    }else{ 
      ol <- FALSE 
    } 
     
    i <- i + 1 
  } 
   
  return(ol) 
} 
 
ratio <- 
function(x){ 
 
  y <- x 
 
  for(i in 1:dim(x)[2]){   
    y[,i] <- x[,i] / x[,1] 
  } 
 
  return(y) 
} 
 
regexval <- 
function(pattern, string, perl=T){ 
  m <- regexpr(pattern, string,perl=T) 
  s <- substring(string, m[1], attributes(m)$match.length + m[1]-1) 
  return(s) 
} 
 
reshapeData <- 
function(idata, simple.cols=TRUE){ 
   
  dat <- idata$DATA 
  dat.length <- dim(dat)[1] 
  dat$id <- factor(rownames(dat)) 
   
  dat.long <-  
    reshape( 
      dat, 
      idvar="id", 
      varying= 
        c( 
          "Area.113", 
          "Area.114", 
          "Area.115", 
          "Area.116", 
          "Area.117", 
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          "Area.118", 
          "Area.119", 
          "Area.121" 
        ), 
      direction="long" 
    ) 
     
  ## Add group classifiers 
  dat.long$id <- rep(dat[, "id"], 8) 
     
  ## Set Coding Variables: Time and Subject 
  for(i in c(1:4)){ 
    dat.long[grep(idata$TAGS.S1[i], dat.long$time), "Time"] <- i 
    dat.long[grep(idata$TAGS.S2[i], dat.long$time), "Time"] <- i 
     
    dat.long[grep(idata$TAGS.S1[i], dat.long$time), "Subject"] <- 1 
    dat.long[grep(idata$TAGS.S2[i], dat.long$time), "Subject"] <- 2 
  } 
     
  ## Simplify column names 
  if(simple.cols){ 
    names(dat.long)[grep("Best.Peptide.Sequence", names(dat.long))]  <- "Peptide" 
    names(dat.long)[grep("Accession.Number", names(dat.long))]  <- "GI" 
    names(dat.long)[grep("Protein.Name", names(dat.long))]  <- "Name" 
  } 
   
  ## Create groups 
  dat.long$Peptide <- factor(dat.long$Peptide) 
  dat.long$Time <- factor(dat.long$Time) 
  dat.long$id <- factor(dat.long$id) 
  dat.long$Subject <- factor(dat.long$Subject) 
     
  idata$DATA.LONG <- dat.long 
   
  return(idata) 
} 
 
setEnvironmentVars <- 
function(...){ 
 
  args <- list(...) 
 
  #create base environment 
  #e <- new.env(parent = baseenv()) 
       
  for(i in 1:length(args)) 
    assign(names(args[i]), args[[i]], env=.GlobalEnv) 
} 
 
siteCount <- 
function(site="K", peptide){ 
  x <- evalq(if(!is.na(grep("N-term", site)[1])) return(1) else(0)) 
  m <- gregexpr(site, as.character(peptide), perl=T)[[1]] 
  if(m[1] > 0) 
      return(length(m)+x) 
  else 
    return(x) 
} 
 
stackSubjects <- 
function(dat, cols.s1, cols.s2){ 
 
  s1 <-  
    data.frame( 
      id = paste( 
              dat$Accession.Number, 
              dat$Start, 
              dat$Stop, 
              dat$Protein.Name, 
              "s1", 
              sep="." 
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            ), 
      dat[,cols.s1] 
    ) 
 
  s2 <-  
    data.frame( 
      id = paste( 
              dat$Accession.Number, 
              dat$Start, 
              dat$Stop, 
              dat$Protein.Name, 
              "s2",              
              sep="." 
            ), 
      dat[,cols.s2] 
    ) 
 
  names(s1) <- c("id", "t0", "t1", "t2", "t3") 
  names(s2) <- c("id", "t0", "t1", "t2", "t3") 
 
  x <- rbind(s1, s2) 
 
  return(x) 
} 
 
sumrat <- 
function(x){ 
  y <- x 
 
  for(i in 1:length(x)){   
    y[i] <- x[i]/x[1] 
  } 
   
  return(y) 
} 
 
testSom <- 
function(som.train, exp.vals){ 
 
  som.proj <- som::som.project(som.train, exp.vals)    
  som.colors <- getSomColors(som.train, som.proj) 
   
  return(som.colors) 
} 
 
trainSom <- 
function( 
    idata,  
    som.xdim=15,  
    som.ydim=12,  
    neigh="bubble",  
    topol="rect",  
    radius=3,  
    alpha=.05 
  ){ 
 
  st.dat <- stackSubjects(idata$DATA, idata$COLS.S1, idata$COLS.S2)   
     
  si <- som.init(st.dat[,2:5], xdim=som.xdim, ydim=som.ydim) 
  st <-  
    som::som.train( 
      st.dat[,2:5],  
      code=si,  
      xdim=som.xdim, 
      ydim=som.ydim,  
      alphaType="linear",  
      neigh=neigh, 
      topol=topol, 
      radius=radius, 
      alpha=alpha 
    ) 
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  return(st) 
} 
 
trimWS <- 
function (x)  
{ 
    x <- sub("[ \t\n\r]*$", "", sub("^[ \t\n\r]*", "", x)) 
    return(x) 
} 
 
unlabeledSiteCount <- 
function( 
  peptide,  
  mod.string,  
  mod.ids=c("K","Y","N-term") 
 ){ 
 
    ##Count Possible Modification Sites 
    sc <- sum(sapply(mod.ids, function(x) siteCount(x, peptide))) 
 
    ## Count Modifications 
    mod.ids <- unique(mod.ids[order(mod.ids)]) 
    mc <- sum(sapply(mod.ids, function(x) modCount(x, mod.string)))   
 
    ## Calculate siteCount - modCount 
    x <- sc-mc 
 
    return(x) 
} 
